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ABSTRACT 
Lin Lin 
 
GENTAMICIN INDUCED INTRACELLULAR TOXICITY IN SACCHAROMYCES 
CEREVISIAE  
 
At the present time, gentamicin is used in the treatment of both Gram-negative 
and Gram-positive bacterial infections.  However, the poorly understood side effect of 
nephrotoxicity is a serious problem and is one of the dose-limiting factors in the use of 
gentamicin.  In our model system, Saccharomyces cerevisiae, which is relatively resistant 
to gentamicin, at least 20 genes are required for gentamicin resistance.  Inspection of the 
physical and genetic interactions of the gentamicin sensitive mutants reveals a network 
centered on the ARF pathway which plays a key role in the regulation of retrograde 
trafficking.  Our studies show that arf1
ts
 arf1∆ arf2∆ cells, gea1ts gea1∆ gea2∆ cells, and 
gcs1
ts
 gcs1∆ glo3∆ cells are all hypersensitive to gentamicin which indicates that 
impaired Arf1 function causes yeast cells to become hypersensitive to gentamicin.  As 
evidence, cellular CPY trafficking and processing are blocked by the presence of 
gentamicin in some of these mutants.  Interestingly, gentamicin can directly affect the 
level of the GTP-bound form of Arf1 in a cell growth phase-dependent manner; even 
though total Arf1 levels in S. cerevisiae are not affected.  As predicted, we also find that 
gentamicin-bound resin can enrich both yeast Arf1-TAP protein and rat Arf1 protein in 
vitro.  With the help of mass spectrometry, we also generated a gentamicin-binding 
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protein list.  Gentamicin hypersensitivity is also observed in S. cerevisiae double deletion 
strains that lack both ARF1 and ARF2 but are kept alive by the presence of hARF4 or 
bARF1.  Increased -1 programmed ribosomal frameshifting efficiency is also observed in 
cells treated with gentamicin.  Finally, a comparison of a gentamicin mixture and four of 
the gentamicin congeners reveals that gentamicin C1 is less toxic than other gentamicin 
congeners or the gentamicin total mixture. 
 
 
Mark G. Goebl, Ph.D., Chair 
 
  
                                                    vii 
 
TABLE OF CONTENTS 
LIST OF TABLES ........................................................................................................... ix 
LIST OF FIGURES ...........................................................................................................x 
ABBREVIATIONS .......................................................................................................... xi 
INTRODUCTION..............................................................................................................1 
1    Chemical Structure of Gentamicin.................................................................................1 
2    Clinical Uses and Side Effects of Gentamicin ...............................................................2 
3    Mechanism of Gentamicin Antimicrobial Activity .......................................................5 
4    Effects of Gentamicin on Eukaryotic Translation Fidelity ............................................7 
4.1 Suppressing nonsense mutations..............................................................................7 
4.2 Programmed ribosomal frameshifting .....................................................................8 
5    Pathway for the Uptaking and Trafficking of Gentamicin  .........................................10 
5.1 Endocytic pathway and retrograded trafficking pathway ......................................10 
5.2 Cellular toxicity induced by an impaired intracellular trafficking pathway ..........10 
5.3 Genome-wide screen of gentamicin sensitive strains ............................................12 
5.4 Targeting the Arf1 pathway ...................................................................................16 
6    Binding of Gentamicin to Other Cytosolic Targets .....................................................19 
7    Other Intracellular Toxicity Hypotheses ......................................................................20 
8    Research Objectives .....................................................................................................21 
MATERIALS AND METHODS ....................................................................................23 
1    Media, Strains and Plasmids ........................................................................................23 
1.1 Bacterial growth media and bacterial cell lysis .....................................................23 
1.2 Yeast growth media and yeast cell lysis ................................................................24 
1.3 Plasmid DNA isolation from bacteria ....................................................................26 
1.4 Plasmid DNA isolation from yeast ........................................................................27 
1.5 Bradford assay .......................................................................................................28 
2    Transformations ...........................................................................................................29 
2.1 Bacterial transformation.........................................................................................29 
2.2 Yeast transformation ..............................................................................................31 
3    SDS-PAGE and Western Blotting ...............................................................................32 
3.1 SDS-PAGE ............................................................................................................32 
3.2 Western Blotting ....................................................................................................33 
3.3 Coomassie Blue Staining and Silver Staining .......................................................34 
4    Dual-luciferase Assay ..................................................................................................35 
4.1 Plasmids sequencing ..............................................................................................35 
4.2 Luciferase Assay System
® .....................................................................................35 
5    GTP-bound ARF1-TAP Pull-down Assay ...................................................................36 
6    Spot Dilution Assay .....................................................................................................37 
7    Carboxypeptidase Y Processing Assay ........................................................................38 
8    Gentamicin-Sepharose 4B Affinity Binding Assay .....................................................38 
9    Mass Spectrometry Analysis of Gentamicin Binding Proteins Assay .........................39 
RESULTS .........................................................................................................................42 
CHAPTER 1: ARF1 PATHWAY IN THE GENTAMICIN RESPONSE OF 
SACCHAROMYCES CEREVISIAE ............................................................................42 
1    Gentamicin Sensitive of arf1
ts
 arf1∆ arf2∆ Strains .....................................................42 
2    Change in GTP-bound Arf1 Protein Level during Different Cell Growth Phases ......45 
                                                    viii 
 
3    Gentamicin Hypersensitivity of Gene Deletion Strains in Different Growth 
Phases ...........................................................................................................................47 
4    Impaired Arf1 Activity and Gentamicin Hypersensitivity...........................................48 
4.1 The loss of Arf-GEF function and gentamicin hypersensitivity ............................49 
4.2 The loss of Arf-GAP function and gentamicin hypersensitivity ...........................52 
5    Cellular CPY Processing in the Absence or Presence of Gentamicin .........................54 
5.1 CPY processing in wild-type cells unaffected by gentamicin ...............................54 
5.2 Disruption of cellular CPY processing in Arf1 or Arf1 regulator mutants by 
gentamicin ..............................................................................................................55 
6    Enrichment of Arf1-TAP Protein by Gentamicin-binding Resin ................................59 
7    Gentamicin Sensitivity of S. cerevisiae Strains with only hArf4 or bArf1 as the 
Functional Arf ..............................................................................................................62 
8    Summary of the ARF1 Pathway in Response to Gentamicin ......................................64 
CHAPTER 2: INCREASE OF -1 PROGRAMMED RIBOSOMAL 
FRAMESHIFTING EFFICIENCY BY GENTAMICIN .............................................66 
1    Confirmation of the Dual-reporter Plasmid Sequence .................................................66 
2    Effect of Gentamicin on -1 Programmed Ribosomal Frameshifting ...........................67 
3    Effect of Gentamicin on +1 Programmed Ribosomal Frameshifting ..........................68 
4    Documented Programmed Ribosomal Frameshifting of Yeast S. cerevisiae ..............69 
5    Consequences of the Programmed Ribosomal Frameshifting Efficiency Changes.....70 
CHAPTER 3: MASS SPECTROMETRY ANALYSIS OF GENTAMICIN 
BINDING PROTEINS.....................................................................................................71 
1    Comparison of Gentamicin-binding Proteins with Existing Data ...............................71 
2    Evaluation of the Gentamicin-binding Protein Dataset ...............................................72 
3    Identification of Functional Protein Complexes and Protein Networks ......................73 
CHAPTER 4: STUDIES OF FOUR GENTAMICIN CONGENERS ........................76 
1    Effects of Gentamicin Congeners on Single Gene Deletion Strains............................76 
2    Effects of Gentamicin Congeners on Arf-GEF and Arf-GAP Mutant Strains ............77 
3    Effects of Gentamicin Congeners on S. cerevisiae Strains with only hArf4 or 
bArf1 as Functional Arf ...............................................................................................77 
CONCLUSIONS ..............................................................................................................79 
TABLES ............................................................................................................................82 
FIGURES ..........................................................................................................................92 
REFERENCES ...............................................................................................................109  
CURRICULUM VITAE   
                                                    ix 
 
LIST OF TABLES 
1. Yeast strains used in this study ......................................................................................82 
2. Plasmids used in this study ............................................................................................84 
3. Measurements of Renilla and Firefly luciferases intensity in YPD media ..................85 
4. Measurements of Renilla and Firefly luciferases intensity in YPD + 500 µg/ml 
gentamicin media .............................................................................. 86 
5. Systematic analysis of -1 PRF and +1 PRF efficiency in the S. cerevisiae in the 
presence or absence of gentamicin (500 µg/ml) ............................................................88 
6. Summary of considered gentamicin-binding proteins from LC-MS/MS ......................89 
7. Gentamicin-binding proteins of the cytoplasmic ribosomal large subunit and the 
cytoplasmic ribosomal small subunit .............................................................................91 
 
  
                                                    x 
 
LIST OF FIGURES 
1. Chemical structures of gentamicin sulfate salt C1, C1a, C2, C2a and C2b ......................92 
2. Plasmids used in the in vivo dual-luciferase assay .........................................................93 
3. Genetic/Physical network of genes necessary for gentamicin resistance ......................94 
4. Sensitivity of yeast ARF1 arf2∆ and arf1ts arf1∆ arf2∆ strains to gentamicin ..............95 
5. Change in GTP-bound Arf1 levels during different cell growth phases .......................96 
6. Gentamicin sensitivity of single gene deletion strains in different growth phases ........97 
7. Gentamicin sensitivity of yeast Arf-GEF mutants .........................................................98 
8. Gentamicin sensitivity of yeast Arf-GAP mutants ........................................................99 
9. Gentamicin sensitivity of Arf-GEF and Arf-GAP mutants in different growth 
phases .........................................................................................................................100 
10. Disruption of cellular CPY processing in Arfs, Arf-GAP, or Arf-GEF mutants by 
gentamicin ..................................................................................................................101 
11. Enrichment of the yArf1-TAP protein and rat Arf1 protein by gentamicin-bound 
resin ............................................................................................................................102 
12. Gentamicin sensitivity of S. cerevisiae strains with only hArf4 or bArf1 as 
functional Arf .............................................................................................................103 
13. Evaluation of the gentamicin-binding protein list ......................................................104 
14. Functional gentamicin-binding protein complexes and protein networks .................105 
15. Sensitivity of single gene deletion strains to gentamicin congeners ..........................106 
16. Sensitivity of Arf-GEF mutants, Arf-GAP mutants, and strains with only bArf1 
or hArf4 as functional Arf, to gentamicin congeners ................................................107 
17. Model of S. cerevisiae in response to gentamicin ......................................................108 
                                                    xi 
 
ABBREVIATIONS 
AP    Adaptor protein 
ARF    ADP-ribosylation factor  
BFA    Brefeldin A 
CCV    Clathrin-coated vesicle 
CF     Cystic fibrosis  
CFTR regulator    Cystic fibrosis transmembrane conductance  
CGN    cis-Golgi network 
COPI    Coat protein complex I 
COPII    Coat protein complex II 
CPY    Carboxypeptidase Y 
DMD     Duchenne muscular dystrophy 
eEF-1 complex    Eukaryotic elongation factor-1 complex 
ER    Endoplasmic reticulum 
GAP     GTPase Activating Protein 
GARP     Golgi-associated retrograde protein complex 
GEF     Guanine Nucleotide Exchange Factor 
Gga proteins    γ-ear adaptin homology Golgi associated Arf-
binding proteins 
HOPS    Homotypic fusion and vacuole protein sorting  
LC-MS    Liquid chromatography-mass spectrometry 
NMD    Nonsense-mediated mRNA decay pathway 
ORF    Open reading frame 
                                                    xii 
 
PRF    Programmed Ribosomal Frameshifting 
RAC      Ribosome-associated chaperone complex 
SGD     Saccharomyces genome database 
TAP     Tandem affinity purification 
TGN     trans-Golgi network 
1 
 
INTRODUCTION 
The discovery of the first aminoglycoside antibiotic, streptomycin, was a 
landmark in the history of antibiotics in 1943.  Streptomycin was the first useful 
antibiotic isolated from a bacterial source and the first effective therapeutic agent against 
Mycobacterium tuberculosis, for which penicillin was largely ineffective (Schatz, Bufie, 
& Waksman, 1944). 
The success of streptomycin led to the subsequent isolation of a large number of 
other aminoglycosides from a variety of producers.  Among them, gentamicin, isolated 
from Micromonospora purpureochromogenes in 1963, constituted a significant advance 
in the treatment of both Gram-negative and Gram-positive bacterial infections (Weinstein 
et al., 1963).  In many cases, gentamicin was the only effective therapeutic tool against 
multidrug-resistant bacterial strains (Appel & Neu, 1978).  At the present time, 
gentamicin is the most widely used aminoglycoside and remains a mainstay of treatment 
of life-threatening Gram-negative bacterial infections, as it is cheap and widely available. 
However, the use of gentamicin is limited by its associated toxicity, involving the 
renal system and the auditory system.  Although once-daily dosage regimens and 
effective monitoring procedures have definitely improved the situation, our knowledge of 
safer gentamicin usage is still insufficient (Buijk et al., 2004).  In this study, my goal was 
to expand our understanding of gentamicin cytotoxicity. 
1   Chemical Structure of Gentamicin 
Commercially available gentamicin sulfate salt is not a single compound but a 
mixture of four active congeners, gentamicin sulfate salt C1, C1a, C2 and C2a (British 
Pharmacopoeia, Volumes I and II, 2008) (Figure 1).  These different congeners have 
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different patterns of methylation modification at the 6‟ position of ring I.  Cobalt was 
demonstrated to stimulate the two C-methylation steps at gentamicin biosynthesis 
(Tipson & Horton, 1978).  Thus, the biosynthesis of gentamicin C2 and gentamicin C1, 
but not C1a or C2b, are cobalt dependent (Kumar, 2008).  All the congeners appear to have 
similar antimicrobial activity (Weinstein, Wagman, Oden, & Marquez, 1967). 
Gentamicin sulfate salts occur as white to buff powders and are soluble in water.  
The amine groups of the gentamicin sugar rings exhibit variable pKa values that range 
from 5.6 to 9.5.  The amine groups on ring I are the most basic (pKa ~ 9.6), whereas 
those on ring II (pKa ~ 5.6 to ~ 8.0) and ring III (pKa ~ 7.5) have pKa values closer to 
physiological pH.  Gentamicin thus carries a net positive charge under physiological 
conditions (pH 7.4) (Wilson, Richard, & Hughes, 1973; Arya, 2007). 
2   Clinical Uses and Side Effects of Gentamicin 
During the first twenty years after its discovery, gentamicin was used extensively 
(Black, Calesnick, Williams, & Weinstein, 1963) mainly because of its antimicrobial 
efficacy at relatively low serum concentration, few resistant organisms, and a relatively 
low prevalence of clinical toxicity (Appel & Neu, 1978).  Currently, it is often used 
clinically in combination with other antimicrobial agents such as β-lactams or 
glycopeptides for the treatment of serious infections with Gram-negative and Gram-
positive organisms. 
Gentamicin is effective against a broad spectrum of both Gram-positive and 
Gram-negative organisms.  Among the responsive Gram-positive groups of 
microorganisms are Staphylococcus aureus (including many penicillin-resistant strains) 
and Streptococcus pyogenes.  Among the clinically more important species of Gram-
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negative organisms responsive to gentamicin are Proteus mirabilis, Pseudomonas 
aeruginosa, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, Salmonella 
typhimurium, and Shigella (Black, Calesnick, Williams, & Weinstein, 1963). 
Gentamicin is a low protein-binding drug (<10%) with a poor degree of oral 
absorption, thus intravenous administration is the usual route in patients with severe 
infections.  After intravenous administrations, the concentration of gentamicin in 
secretions and most tissues is low.  However, high concentrations are found in renal 
cortical tissue and the hair cells of the inner ear. 
After it is freely filtered through the glomerulus in the kidney without being 
metabolized, most of the intravenously administered gentamicin is excreted into the 
urine.  But about 10% of the dose accumulates in the renal cortex where ultrafiltration 
occurs; thus, the gentamicin concentration in the renal cortex can be several times higher 
than in the serum (reviewed in Chambers, 2001).  Gentamicin could also remain in the 
renal cortex due to its long half-life there (100 hours comparing to 30 minutes in the 
plasma), which makes renal damage worse (Luft, 2002).  Molecular level studies showed 
that, following glomerular filtration, gentamicin can diffuse from the tubular lumen to the 
apical membranes of renal proximal tubular cells (reviewed in Schrier, 1999).  By 
binding to the negatively charged phospholipid-binding sites on the brush border of the 
apical membranes, gentamicin enters the cell mainly by megalin-mediated endocytosis.  
Megalin is an endocytic receptor protein which is most abundantly expressed in the renal 
proximal tubular cells (Moestrup et al., 1995).  A small but toxicologically important 
portion of the administered gentamicin is then accumulated in the proximal tubule cells.  
Gentamicin-induced nephrotoxicity is characterized by tubular necrosis which mainly 
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involves the proximal tubule cells, a slow rise in serum creatinine, and a marked decrease 
in the glomerular filtration rate (GFR). 
Unlike gentamicin-induced nephrotoxicity, gentamicin-induced ototoxicity is 
more related to the peak serum level of gentamicin during treatment (reviewed in 
Selimoglu, 2007).  Gentamicin can accumulate in the endolymph and perilymph of the 
inner ear and injures hair cells also by megalin-mediated endocytosis.  Some mutations 
on the human mitochondrial 12S ribosomal RNA gene have been previously reported to 
predispose carriers to gentamicin-induced ototoxicity (reviewed in Fischel-Ghodsian, 
2005).  Thus, the prevention of gentamicin-induced ototoxicity through family history 
and molecular diagnosis is possible in many cases. 
Since an accumulation from multiple doses or a high serum concentration of 
gentamicin can lead to nephrotoxicity and ototoxicity, clinicians proposed that the serum 
level of gentamicin should always be carefully monitored (Bennett et al., 1979).  
Traditionally, gentamicin was administered 2-3 times daily.  As an improvement, recent 
insight into the pharmacodynamics of gentamicin has suggested once-daily dosing 
regimens which include all the 2-3 separated daily dosage.  Clinicians have demonstrated 
the efficacy, safety, and economy of the 24-hour dosing interval, resulting in it becoming 
the standard for gentamicin administration (Nicolau et al., 1995; Barza et al., 1996; Ward 
& Theiler, 2009). 
However, gentamicin still induces a dose-dependent nephrotoxicity in 10-25% of 
therapeutic courses, despite rigorous monitoring of serum drug concentration and once-
daily dosing regimens (Hatala et al., 1996). 
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The differences in chemical structures among the gentamicin congeners are 
similar to the differences between gentamicin and some other aminoglycosides, such as 
tobramycin or netilmicin (United States Pharmacopoeial Convention, 1995).  It was 
reasonable to assume that even though all the major gentamicin congeners, C1, C1a, C2 
and C2a, appear to have similar antimicrobial activity (Weinstein et al., 1967), they 
exhibit different cellular toxicity and nephrotoxicity in vivo (Sandoval et al., 2006).  
Among them, congener C1 (previously identified as C2) exhibited the least cellular 
toxicity and no nephrotoxicity (Sandoval et al., 2006). 
3   Mechanism of Gentamicin Antimicrobial Activity  
Since their discovery, the biochemical modes of action of aminoglycosides have 
long been topics of great interest.  A series of genetic and biochemical studies in the late 
1950s and early 1960s proposed the ribosome as the probable target for the antibacterial 
actions of many aminoglycosides (Erdos & Ullmann, 1959).  But the ribosome exceeds 
the size of an average aminoglycoside by four orders of magnitude and presents multiple 
sites for aminoglycoside binding.  It was only after the advent of ribosome 
crystallography that detailed views of the ribosome-gentamicin interactions at atomic 
resolution were revealed (reviewed in Tenson & Mankin, 2006). 
The bacterial ribosomal small subunit, which is called the 30S subunit, contains 
an RNA chain (16S) and 20-21 proteins.  When elongation proceeds, the small subunit 
provides the decoding center, which possesses three tRNA-binding sites, A (aminoacyl), 
P (peptidyl) and E (exit) sites.  Decoding requires the correct codon-anticodon 
recognition and thus controls translation fidelity. 
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Gentamicin is positively charged at biological pH, which contributes to its rRNA 
binding.  Gentamicin-binding affects ribosome accuracy at the initial step of aminoacyl-
tRNA selection.  Ribosome crystallography reveals that when there is no gentamicin 
around, two conserved adenine residues on the decoding center aminoacyl-tRNA site (A 
site) of 16S rRNA at positions 1492 and 1493 (E. coli numbering) (Yoshizawa et al., 
1998; Ogle et al., 2001) always stack in the internal loop of helix 44.  The binding of 
mRNA and cognate tRNA in the A site induces A1492 and A1493 to flip out of the 
internal loop of helix 44 and to issue an approval signal from the decoding center.  In the 
presence of bound gentamicin in helix 44, conformation changes happen in the decoding 
center.  As a result, A1492 and A1493 flip out and always stay out of the internal loop of 
helix 44, even upon the binding of a near-cognate tRNA.  During translation initiation, 
gentamicin interferes with the binding of fMet-tRNA and the formation of the initiation 
complex.  During translation elongation, gentamicin increases the frequency of amino 
acid misreading and the bacteria die because they are unable to synthesize proteins vital 
to its growth. 
Though chemically distinct, aminoglycoside antibiotics that contain ring I and II 
all bind in the same RNA pocket through similar hydrogen bonding networks.  Additional 
rings (like ring III of gentamicin) contribute to binding affinity and assist in the correct 
orientation of rings I and II by creating additional drug-RNA contacts (Tenson & 
Mankin, 2006). 
Gentamicin congeners bind to the 16S rRNA at the same binding site but with 
different affinities (Yoshizawa et al., 1998).  Gentamicin C1a binds to 16S rRNA with a 
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slightly higher affinity (Kd = 0.01 µM) than C2 (Kd = 0.025 µM), whereas C1 binds with 
the lowest affinity compared to the others (Kd = 0.5 µM). 
Although the eukaryotic ribosome is much more resistant to aminoglycosides, 
there is similarity between prokaryotic and eukaryotic protein synthetic machinery.  
Aminoglycoside antibiotics bind to the 18S rRNA in the eukaryotic ribosomal small 
subunit but, compared to the binding to the prokaryotic 16S rRNAs, with a 1-2 orders of 
magnitude lower binding affinity (Fan-Minogure, 2007; Recht et al., 1999). 
4   Effects of Gentamicin on Eukaryotic Translation Fidelity  
4.1 Suppressing nonsense mutations 
Interestingly, over twenty years ago, clinicians found that cystic fibrosis (CF) 
patients, who commonly require gentamicin as an antibiotic to treat P. aeruginosa upper 
respiratory infections by both intravenous administration and inhalation, were able to 
tolerate the drug and experienced less nephrotoxicity (Stephens et al., 1983; McCracken, 
1986).  Further investigation elucidated that cystic fibrosis is caused by mutations in the 
gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein.  
Among all the mutations, the CFTR mutations generating premature stop codons lead to 
nonsense-mediated CFTR mRNA decay and result in a very small amount of protein 
product (reviewed in Kerem, 2004). 
Bedwell‟s laboratory first reported in their transgenic mouse model, which 
expresses a human CFTR mutant (CFTR-G542X) in an animal lacking endogenous 
mouse CFTR (Cftr
-/-
), that gentamicin can suppress the premature termination of CFTR.  
Later, they also reported that gentamicin can increase the abundance of CFTR mRNA and 
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partially restore the expression of functional CFTR protein in both human cell lines and 
their transgenic mouse model (Howard et al., 1996; Du et al., 2002; Du et al., 2006). 
At the molecular level, studies showed that gentamicin can suppress premature 
stop codon mutations by disrupting translational fidelity.  By allowing the incorporation 
of near-cognate tRNA at the premature codon on transcripts, gentamicin helps translation 
to continue until the normal stop codon in the transcript is reached (Sermet-Gaudelus, 
2007).  Gentamicin also prevents nonsense-mediated mRNA decay since the ribosome 
can translate through the premature termination codon.  However, the susceptibility to 
suppression depends on the premature stop codon itself and on the sequence context 
surrounding the premature stop codon (Phillips-Jones et al., 1995). 
Nevertheless, the ability of gentamicin to correct other nonsense mutation 
diseases, like Duchenne Muscular Dystrophy (DMD), in vivo has been reported (Barton-
Davis, 1999). 
Currently, gentamicin and other aminoglycosides are widely considered potential 
therapeutics for the treatment of many diseases resulting from nonsense mutations (Phase 
III Clinical trials gov identifier: NCT00803205, Study of Ataluren (PTC124™) in Cystic 
Fibrosis; Phase I Clinical trials gov identifier: NCT00451074, Six Month Study of 
Gentamicin in Duchenne Muscular Dystrophy with Stop Codons).  Gentamicin may also 
prove to be beneficial in cancers, such as colon cancer, that result from nonsense 
mutations in tumor suppressor genes (Kaufman, 1999). 
4.2 Programmed ribosomal frameshifting 
Despite rigorously maintaining the reading frame of mRNA molecules to be 
translated into proteins, ribosomes also make programmed slips by one base towards 
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either the 5‟(-1) or the 3‟ (+1) direction during translation (Jacks & Varmus, 1985).  This 
programmed ribosomal frameshifting is controlled by frameshifting signals, including 
special sequence information and structural elements in mRNA molecules (Farabaugh, 
1996; Harger et al., 2002).  Viruses use this mechanism to increase the protein-coding 
capacities of their genomes, whose sizes are limited due to the small volumes of viral 
capsids into which they are packaged (Farabaugh, 1996).  Programmed frameshifting was 
first discovered in viruses, but it has also been observed in prokaryotic and eukaryotic 
systems (Jacks & Varmus, 1985; Muldoon-Jacobs & Dinman, 2006; Lux et al., 2010).   
The yeast S. cerevisiae has proven to be an ideal model system to study 
programmed ribosomal frameshifting.  Researchers have observed that the deletion of 
any member of the conserved nascent peptide-associated complex, especially the deletion 
of SSZ1, ZUO1, or SSB1/SSB2, can inhibit -1 programmed ribosomal frameshifting but 
has no effect on +1 programmed ribosomal frameshifting (Muldoon-Jacobs & Dinman, 
2006). 
Our goal was to clarify the effect of gentamicin on programmed ribosomal 
frameshifting efficiency since it has not been reported in the literature.  Recently, an 
in vivo dual-luciferase assay was developed to improve the previous lacZ-luciferase 
bicistronic reporter system (Harger & Dinman, 2003) (Figure 2).  The frameshifting 
signals in the new dual-luciferase assay are inserted between the Renilla and firefly 
luciferase reporter genes, and the two activities can be directly measured in cell lysates in 
a single tube. 
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5   Pathway for the Uptaking and Trafficking of Gentamicin 
5.1 Endocytic pathway and retrograded trafficking pathway 
The complete picture of how gentamicin induces nephrotoxicity involves multiple 
intracellular mechanisms.  Gentamicin is taken up through the endocytic pathway like 
other cellular toxins such as cholera.  Then, gentamicin is trafficked in a retrograde 
fashion through the Golgi apparatus to the endoplasmic reticulum, from where it is finally 
released into the cytosol (Kahn et al., 1991; Moss & Vaughan, 1995).  It has been shown 
that gentamicin sequestered in the vacuoles or trafficked in a retrograde fashion through 
the secretory pathway is nontoxic; however, the gentamicin released into the cytosol is 
toxic (Sandoval & Molitoris, 2004). 
5.2 Cellular toxicity induced by an impaired intracellular trafficking pathway  
Previous research in the Molitoris‟ laboratory (Indiana University School of 
Medicine) has shown that gentamicin accumulated by proximal tubule cells is mainly 
localized within endosomes, lysosomal vacuoles, and the Golgi apparatus (Sandoval 
et al., 1998; Sandoval et al., 2000).  Because gentamicin is positively charged in 
endosomes (pH = 5.9~6) and lysosomes (pH = 4.8~5), it is believed that gentamicin is 
unable to pass across the membranes and act outside of endosomes or lysosomes.  But, 
when lysosome permeability is changed, gentamicin is released into the cytosol more 
quickly and gentamicin-induced cellular toxicity can be severe (Sandoval & Molitoris, 
2004; Servais et al., 2005). 
In the model system Bakers yeast S. cerevisiae, further investigation revealed that 
the deletion of any of the four genes encoding the protein components of the Golgi-
associated retrograde protein (GARP) complex causes sensitivity to gentamicin (Wagner 
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et al., 2006).  GARP is a membrane-tethering complex that facilitates retrograde transport 
of endosome vesicles which can then fuse into the trans-Golgi network.  Defects in the 
GARP complex may cause defects in retrograde trafficking from endosomes back to the 
Golgi and lead to vacuole fragmentation (Conibear et al., 2003).  Blackburn and Avery 
found that cells lacking Vps54 (Luv1), a component of the GARP complex, have 
increased sensitivity to gentamicin (Blackburn & Avery, 2003).  Our laboratory further 
demonstrated that cells lacking other components of the GARP complex, Vps51, Vps52, 
or Vps53, are also hypersensitive to gentamicin (Wagner et al., 2006).  In the GARP 
complex, Vps52, Vps53 and Vps54 form a complex in a 1:1:1 ratio (Conibear & Stevens, 
2000).  If one of these proteins is missing, the other two proteins become unstable.  
Vps51 is assembled with Vps52, Vps53 and Vps54 and also binds the t-SNARE protein 
Tlg1, which is in close proximity to the t-SNARE protein Tlg2 (Piper et al., 1994).  
Vps45 is a key regulator of the GARP pathway (Bryant & James, 2001).  The absence of 
Vps45 results in strong gentamicin hypersensitivity also (Wagner et al., 2006).  Vps45 is 
a member of the Sec1/Munc-18 (SM) family, whose members have essential roles in 
regulating multiple membrane transport pathways.  When yeast cells lack the SM protein 
Vps45, the t-SNARE Tlg2 can still be targeted to the correct intracellular location.  
However, Tlg2 is non-functional and unable to bind its cognate SNARE binding partners 
Tlg1 and Vti1.  Vps45 acts as a chaperone-like molecule for its cognate t-SNAREs and 
plays an essential role in the activation process, allowing its cognate t-SNAREs to 
participate in ternary complex formation (Bryant & James, 2001). 
The yeast counterpart of the mammalian lysosome is the vacuole. the Goebl 
laboratory has also tested strains that have deletions of different genes encoding proteins 
12 
 
that are components of the homotypic fusion and vacuole protein sorting (HOPS) 
complex (Wagner et al., 2006).  The HOPS complex, consisting of Pep3, Pep5, Vam6, 
Vps16, Vps33, and Vps41, is critical for proper tethering of endosomal vesicles to the 
vacuolar membrane (Seals et al., 2000).  Mutants lacking Vps16 or Vps41 of the HOPS 
complex have increased sensitivity to gentamicin.  Cells lacking the HOPS complex 
associated protein Vps8 also have increased sensitivity to gentamicin.  The HOPS 
complex acts as a guanine nucleotide exchange factor (GEF) for the Rab-like protein 
Ypt7.  The HOPS complex facilitates nucleotide exchange on Ypt7.  Thus the HOPS 
complex functions as a Ypt7 effector.  In yeast, vacuole SNARE complexes bind to either 
Sec17 or the HOPS complex, but not both (Collins et al., 2005).  Sec17 and its co-
chaperone Sec18 disassemble SNARE complexes.  Ypt7 regulates the reassembly of 
unpaired SNAREs with each other and with the HOPS complex, forming HOPS·SNARE 
complexes prior to fusion.  Thus, Sec17 and Ypt7-regulated HOPS have mutually 
exclusive interactions with vacuole SNAREs.  They mediate SNARE complex disruption 
and assembly for docking and fusion respectively. 
5.3 Genome-wide screening for gentamicin sensitive strains 
To identify genes that are required for gentamicin resistance in the yeast 
S. cerevisiae, Blackburn and Avery tested a library of the yeast S. cerevisiae, which 
contained defined deletions of each single nonessential yeast gene, for gentamicin 
hypersensitivity (Blackburn & Avery, 2003).  Among approximately 4,800 defined 
deletion strains, seventeen mutants are hypersensitive to gentamicin as compared to the 
wild-type parent strain.  Genome-wide screening was carried out on the yeast extract-
peptone-dextrose (YPD) medium plates either in the absence or presence of gentamicin.  
13 
 
When the seventeen deletion strains were moved to YPD liquid medium, only some of 
them showed growth inhibition in the presence of gentamicin (Wagner et al., 2006).  The 
deletion strains with clear growth inhibition in the presence of gentamicin were: vps54∆, 
vps16∆, zuo1∆, vps15∆, sac1∆, gcs1∆, and ydr455c∆ (the dubious open reading frame 
which partially overlaps with NHX1).  The gene products Vps54 (a member of the GARP 
complex) and Vps16 (a member of the HOPS complex) were discussed in the previous 
section. 
Zuo1 is a cytosolic ribosome-associated chaperone which contains a dnaJ domain 
and functions as a J-protein partner (Conz et al., 2007; Gautschi et al., 2001).  The 
dnaJ/Hsp40 is a family of proteins that regulates Hsp70 chaperone activity.  All dnaJ 
homologs contain a highly conserved 75-amino acid J domain, which interacts with the 
ATPase domain of Hsp70 to stimulate ATP hydrolysis.  DnaJ homologs thus stimulate 
the intrinsically weak ATPase activity of Hsp70 proteins and facilitate the interaction 
between Hsp70 and polypeptide substrates (Huang et al., 2005).  Along with the Hsp70-
related protein Ssz1in the yeast S. cerevisiae, Zuo1 forms the ribosome-associated 
complex (RAC), which stimulates the ATPase activity of the Hsp70 proteins Ssb1 and 
Ssb2.  Together, Zuo1, Ssb1/Ssb2 and Ssz1 act as a molecular chaperone complex to 
facilitate protein folding of nascent polypeptide chains.  Mutations in ZUO1, SSB1/SSB2 
and SSZ1 lead to improper translation termination and inhibition of -1 ribosome 
frameshifting (Muldoon-Jacobs & Dinman, 2006). 
Vps15 is a serine/threonine protein kinase that functions with Vps34 to form a 
membrane-associated signal transduction complex.  VPS34 was also suggested to be 
required for gentamicin resistance in the yeast S. cerevisiae (Blackburn & Avery, 2003).  
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The Vps15/Vps34 complex is the only known phosphatidylinositol 3-kinase in the yeast 
S. cerevisiae (Herman & Emr, 1990).  Vps15 and Vps34 are the regulatory subunit and 
the catalytic subunit of the complex, respectively.  The recruitment of Gpa1, which is a 
mating specific protein, promotes the activation of the complex (Slessareva et al., 2006).  
Notably, both Vps15 and Vps34 are necessary for recruitment of Gpa1 to the endosome.  
Gpa1 is the GTP-binding α-subunit of a heterotrimeric G protein and can be activated by 
GEF proteins (Slessareva et al., 2006).  Vps15 binds directly to the inactive (GDP-bound) 
form of Gpa1 while Vps34 directly engages the active (GTP-bound) form of Gpa1.  
When engaged to active Gpa1, Vps34 is stimulated from its basal activity and the 
production of phosphatidylinositol 3-phosphate is increased (Herman & Emr, 1990). 
Sac1 is an integral membrane phosphatidylinositide phosphatase.  Sac1 functions 
along with the phosphatidylinositol 4-kinases, Pik1, Stt4, and Lsb6 at Golgi membrane 
and the nuclear membrane, the plasma membrane, or both the vacuolar and the plasma 
membranes, respectively (Walch-Solimena & Novick, 1999; Cutler et al., 1997; Han 
et al., 2002).  SAC1 mutants accumulate PtdIns(4)P at the ER and vacuolar membranes, 
which in turn results in altered late endocytic and vacuolar trafficking (Tahirovic et al., 
2005).  Mutations in Stt4, but not in Pik1p or Lsb6p, compensate for this defect (Cutler 
et al., 1997).  SAC1 mutants also display defects in endosomal trafficking and synthetic 
interactions with mutations in a variety of genes involved in the vacuolar protein sorting 
pathway (Walch-Solimena & Novick, 1999). 
Gcs1 is a GTPase activating protein (GAP) for ADP-ribosylation factors (Arfs, 
including Arf1, Arf2, and Arf3 in the yeast S. cerevisiae) (Blader et al., 1999).  Arfs were 
originally identified as cofactors of cholera toxin and more recently recognized as 
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essential participants in intracellular vesicular transport (Kahn et al., 1991; Moss & 
Vaughan, 1995).  Arfs are small GTPases and members of the Ras superfamily which can 
cycle between active-GTP-bound and inactive-GDP-bound conformations (Roth, 1999; 
Gillingham & Munro, 2007).  Guanine nucleotide exchange factors (GEF) can activate 
Arfs to a GTP-bound conformation while GTPase activating proteins (GAP) can 
deactivate Arfs to a GDP-bound conformation.  Sec7, Gea1 and Gea2, and Syt1 have 
been identified as Arf1 GEF proteins.  The temperature sensitive GEA mutants were 
found to have defects in ER-to-Golgi and intra-Golgi transport (Peyroche et al., 1996).  
Gcs1, Glo3, and Age2 are Arf1 GAP proteins.  Among them, Gcs1 and Age2, an 
essential Arf GAP pair, provide an overlapping function for vesicle transport from the 
trans-Golgi network to the vacuole and late endosomes.  Gcs1 and Glo3, another essential 
Arf GAP pair, also provide an overlapping function for vesicle retrograde transport from 
the Golgi to the ER (Poon et al., 2001).  Furthermore, a gcs1∆ strain was found to be 
weakly hypersensitive to gentamicin (Blackburn & Avery, 2003).  Much like other 
GTPases, the Arfs do not efficiently hydrolyze GTP in the absence of an Arf1 GAP 
(Randazzo et al., 1994).  These GEFs and GAPs play an important role in regulating Arf1 
activity.  I will explore the ARF1 signaling pathway in greater detail in my dissertation. 
The NHX1 gene is present on the opposite DNA strand but overlaps YDR455C.  
Nhx1 is an endosomal Na
+
/H
+
 exchanger.  It has been well established that luminal 
acidification of the endocytic components, including endosomes and the 
lysosome/vacuole, is required for endosomal maturation, receptor recycling, and vesicle 
targeting (Brett et al., 2005).  Loss of Nhx1 confers growth sensitivity to low pH stress 
and trafficking defects, which can be alleviated by weak bases (Bowers et al., 2000).  
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Previous studies have also shown that gentamicin can inhibit the Nhx1 Na
+
/H
+
-ATPase 
in vivo (Ali et al., 1995).  Furthermore, these investigators demonstrated that gentamicin 
inhibits the Na
+
/H
+
-ATPase in renal tubule cells only when the Na
+
/H
+
-ATPase is 
accessible from the cytoplasm (Fukuda et al., 1991). 
5.4 Targeting the Arf1 pathway 
The Arfs are structurally and functionally conserved proteins of approximately 
21 kDa, and are members of the Ras superfamily of regulatory GTPases (reviewed in 
Pucadyil & Schmid, 2009).  In S. cerevisiae, three Arfs have been identified, Arf1, Arf2, 
and Arf3.  Arf1 and Arf2 are 96% identical in amino acid sequence and are functionally 
interchangeable and form an essential pair of proteins (Stearns et al., 1990).  Arf1 is an 
abundant protein, and the level of protein produced from ARF1 is approximately 10-fold 
higher than that from ARF2 (Stearns et al., 1990).  While an arf2∆ strain displays no 
growth phenotype, arf1∆ strains grow slowly, are cold sensitive, and are fluoride 
hypersensitive.  It is likely that the genetic differences between mutations in ARF1 and 
ARF2 are due to differences in the level of expression of the two proteins (Kahn et al., 
1991; Moss & Vaughan, 1995).  ARF3 does not compensate for the loss of ARF1 and 
ARF2, and an arf1∆arf2∆ double deletion strain is inviable despite the presence of Arf3 
(Stearns et al., 1990).  Hereafter, I will focus on the ARF1 pathway signaling. 
Based on genetic interactions between hypersensitive mutants and their products, 
we proposed that the ARF1 pathway itself is a target and is affected by gentamicin 
(Figure 3). 
The ARF1 pathway plays a critical role in chitin synthesis in yeast S. cerevisiae.  
Chitin is a long-chain polymer of N-acetylglucosamine and it is a major cell wall 
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component (Trautwen et al., 2005).  By controlling the sporulation-specific protein Sps1, 
the ARF1 pathway regulates the subcellular localization of the chitin synthase protein 
Chs3 (Iwamoto et al., 2005).  CHS1 encodes another chitin synthase whose subcellular 
localization is not regulated by Sps1 (Ziman et al., 1998) but is also required for 
gentamicin resistance (Blackburn & Avery, 2003).  CAX4 and MNN9 encode 
glycosylation enzymes essential for cell wall synthesis (Ram et al., 1994) and are also 
required for gentamicin resistance (Blackburn & Avery, 2003). 
The phosphatidylinositol 3, 4, 5-trisphosphate can activate Arf -nucleotide 
exchange factors through their Pleckstrin homology domain (PH domain) and their Sec7 
domain directly and, in turn, up-regulate Arf1 activity (Klarlund et al., 1997).  The 
phosphatidylinositol 3, 4, 5-trisphosphate is regulated by phosphatidylinositide 
phosphatase Sac1 and phosphatidylinositol kinases Vps15/Vps34 and Pik1 which are all 
required for gentamicin resistance (Blackburn & Avery, 2003). 
As mentioned previously, both the HOPS and GARP complexes regulate 
Ypt/Rab‟s.  The Arfs and Ypt/Rabs are two families of GTPases and are key regulators of 
vesicular transport.  While Arfs are implicated in vesicle budding from the donor 
compartment, Ypt/Rab‟s are involved in the targeting of a vesicle to an acceptor 
compartment (Kawasaki, Nakayama, & Wakatsuki, 2005).  Interestingly, several proteins 
that belong to the Sec7-domain family exhibit distinct genetic interactions with 
Ypt/Rab‟s (Jones et al., 1999) which lead to the proposal that an Ypt-Arf GTPase cascade 
exists in the secretory pathway. 
The Arfs have an important role in regulating secretory membrane transport and 
modulating Golgi structure (reviewed in D‟Souza-Schorey & Chavrier, 2006; Spang, 
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2002).  Arf1 regulates the composition of secretory and endocytic organelles by 
recruiting the vesicle coat proteins COPI and clathrin in S. cerevisiae.  Importantly, the 
recruiting of clathrin is through the clathrin-coated cargo adaptor proteins, AP-1, AP-2, 
AP-3, AP-4, Gga1 and Gga2 in S. cerevisiae.  The Gga proteins are ubiquitous Golgi-
localized adaptor proteins which can interact with Arf1 and Arf2 in a GTP-dependent 
manner (Puertollano et al., 2001).  We will utilize the binding ability of Gga2 to Arf1-
GTP in our experiments. 
Although Arf1 is soluble when bound to GDP, it can associate with membranes 
because of the N-terminus myristoylation (covalent attachment of myristate, a 14-carbon 
saturate fatty acid, to the N-terminal glycine, [Franco et al., 1995]).  N-Myristoylation 
promotes weak and reversible protein-membrane and protein-protein interactions.  This 
lipid modification appears to be important for Arf1 association with membranes 
(Goldberg, 1998).  Recent research showed that the myristoyl group inhibits the 
interaction of Arf1 with its nucleotide exchange elements, unless there is a membrane 
surface available which can accommodate the myristoyl chain.  So nucleotide exchange 
can only happen after the association of the myristoyl group with a membrane surface 
(Liu et al., 2009). 
Brefeldin A (BFA) has been a very useful tool for cell biologists studying the 
structure and function of intracellular organelles, particularly the Golgi apparatus of 
mammalian cells.  The structure of the Golgi complex is severely perturbed after only a 
few minutes of BFA treatment.  After ten minutes of exposure to the drug, the Golgi 
complex disassembles and fuses with the endoplasmic reticulum (ER) (Lippincott-
Schwartz et al., 1989).  In permeable strains of the yeast S. cerevisiae, similar BFA 
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induced changes in Golgi morphology can be observed (Peyroche et al., 1996).  It was 
later established that Brefeldin A could stabilize the abortive Arf1-GDP-Sec7 domain 
complex (the Sec7 catalytic domain was from Gea1 in this study) and prevent Arf1 from 
being activated by Arf GEF through the Sec7 domain (Chardin & McCormick, 1999). 
6   Binding of Gentamicin to Other Cytosolic Targets  
The binding ability of gentamicin to some protein partners has been described.  
Horibe et al. (2004) applied a protein pull-down assay to a gentamicin-Sepharose column 
and analyzed the pull-down proteins by 1D SDS-PAGE (Horibe et al., 2004).  
Calreticulin (CRT, UniProtKB: P52193) was suggested to bind to gentamicin directly 
in vitro with a KD value of 3.85×10
-4
 M.  The binding of ribostamycin to the protein 
disulfide isomerase (PDI, UniProtKB: P05307) (with a KD value of 3.19×10
-4
 M), the 
binding of gentamicin to the heat shock protein 90 kDa beta member (GRP94, 
UniProtKB: Q95M18) (without a KD value), and heat shock protein 70 kDa (HSP73, 
UniProtKB: CAN13333 and CAN87708) (without a KD value) were all elucidated 
through the same experimental strategy (Miyazaki et al., 2004; Horibe et al., 2001).  
However, it still remains unclear whether all the proteins that can bind to gentamicin 
have been identified. 
One of the limitations of the previous experimental method is the poor resolution 
of one-dimensional SDS-PAGE, because only abundant proteins which form strong 
Coomassie Blue stained bands can be identified.  During the past two decades, mass 
spectrometry has become established
 
as the primary method for protein identification 
from complex
 
mixtures of biological origin.  With the power of mass spectrometry, we 
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reasoned that less abundant gentamicin binding proteins in pull-down mixtures could be 
identified. 
7   Other Intracellular Toxicity Hypotheses 
A few more hypotheses have been suggested for the mechanisms of gentamicin 
intracellular toxicity, including induction of hydroxyl radical mediated tissue injuries, 
apoptosis through the mitochondrial pathway, and increased renal cortical 
phospholipidosis. 
Gentamicin was found to form complexes with mitochondrial Fe
2+
 to catalyze the 
formation of superoxide anions, hydrogen peroxide, hydroxyl radicals, and water (Walker 
& Shah, 1988).  Hydroxyl radicals are strong mediators of tissue injury.  Hydroxyl 
radicals can oxidize a wide variety of organic compounds including polyunsaturated fatty 
acids, leading to cell membrane injury and protein degradation (Beckman et al., 1990).  
Hydroxyl radicals also play a role in toxic acute renal failure (reviewed in Baliga et al., 
1999).  Notably, scavengers of reactive oxygen metabolites as well as iron chelators 
provide protection from gentamicin-induced nephrotoxicity (Paller et al., 1984). 
Gentamicin can also increase caspase-9 and caspase-3 activities and, in turn, 
activate apoptosis in renal cell lines and embryonic rat fibroblasts (Mouedden et al., 
2000) through the mitochondrial apoptosis pathway (Servais et al., 2004). 
The binding of gentamicin to phosphatidylinositol, which lies in lipid bilayers, 
can cause lipid aggregation (Bambeke et al., 1995) and inhibit the activities of 
phospholipases (Hostetler & Hall, 1982).  Although neither phospholipid accumulation 
nor phospholipase inhibition alone can explain cell death, the extent of phopholipidosis 
21 
 
induced by most aminoglycosides correlates well with their nephrotoxic potential 
(Laurent et al., 1982). 
8   Research Objectives 
The overall objective of this research project is to expand our understanding of 
the mechanisms of gentamicin cytotoxicity.  However, this study is difficult in 
mammalian cells due to their inherent complexity.  Therefore, given the tremendous 
genetic, genomic and proteomic advantages of yeast, and demonstrated similarities 
between yeast and mammalian cells, we have begun to utilize yeast to understand the 
pathway(s) important in inducing gentamicin toxicity.  Specifically, Aim 1 and Aim 4 of 
this study are centered on the ARF1 pathway which plays a key role in the regulation of 
retrograde trafficking from the Golgi-to-the ER in vivo.  In brief, four specific aims are 
addressed to achieve this task. 
Aim 1 was to elucidate the role of the Arf1 pathway in gentamicin toxicity.  Since 
we hypothesize that the Arf1 pathway is one of the intracellular targets of gentamicin, we 
examined whether ARF1, ARF1-GEF, or ARF1-GAP mutant strains are more sensitive to 
gentamicin.  I also examined how gentamicin affects the Arf1 pathway at the molecular 
level.  My objective is to clarify the specific target of gentamicin in the intracellular 
trafficking pathway. 
Aim 2 was to explore whether gentamicin can affect translation fidelity in 
eukaryotes, and lead to programmed ribosomal frameshifting efficiency changes in vivo.  
Studies have shown that gentamicin can suppress premature termination codons by 
disrupting translational fidelity (Sermet-Gaudelus, 2007).  However, it has not been 
reported in the literature whether gentamicin can affect the efficiency of programmed 
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ribosomal frameshifting in vivo.  Since S. cerevisiae is an ideal model system to study 
programmed ribosomal frameshifting (Harger & Dinman, 2003), my aim was to elucidate 
the programmed ribosomal frameshifting efficiency changes which may play a role in the 
translational regulation of gene expression. 
Aim 3 was to identify all the gentamicin-binding proteins in S. cerevisiae.  Some 
proteins have shown to potentially bind to gentamicin in vitro (Horibe et al., 2001; 
Miyazaki et al., 2004; Horibe et al., 2004).  However, because of the poor resolution of 
one-dimensional SDS-PAGE, it still remains a question as to whether all the proteins that 
can bind to gentamicin have been identified.  In our aim, with the power of mass 
spectrometry, we reasoned that lower abundant gentamicin-binding proteins would be 
identified. 
Aim 4 was to test purified gentamicin congeners (including C1a, C1, C2 and C2a) 
on mutant strains with impaired Arf1 activity.  Different congeners exhibit different 
cellular toxicity and nephrotoxicity in vivo (Sandoval et al., 2006).  It is our interest to 
test the congeners in yeast ARF1 mutant strains and Arf-GEF, or Arf-GAP mutant strains, 
and to clarify which congener is the least toxic.  This result will help us to meet the long-
term goal of developing practical therapeutic approaches for better using gentamicin. 
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MATERIALS AND METHODS 
1    Media, Strains and Plasmids 
1.1 Bacterial growth media and bacterial cell lysis 
Bacterial strains (E. coli) were cultured at 37°C in LB medium (1% Bactotryptone 
(w/v), 0.5% yeast extract (w/v), and 1% NaCl (w/v)) unless otherwise indicated.  
Ampicillin and other antibiotics were added after autoclaving as indicated.  Solid LB 
medium was made with an additional final concentration of 2% agar (w/v). 
Bacteria were lysed in 1× PBS containing 1× Complete protease inhibitor cocktail 
(Roche, Indianapolis, IN) lysis buffer unless otherwise indicated.  10× PBS solution was 
made as a stock (1.4 M NaCl, 27 mM KCl, 101 mM Na2HPO4, and 18 mM KH2PO4, 
pH 7.3).  To lyse bacterial cultures, freeze/thaw cycles were used with bacterial cell 
suspensions of up to 1.2 ml.  Sonication was applied to bacterial cell suspensions with 
volumes larger than 1.2 ml. 
For freeze/thaw cycle lysis, bacterial were collected by centrifugation (4,500 g for 
10 minutes).  Cells were resuspended in 1× lysis buffer.  1 µl of 10 mg/ml lysozyme 
solution was added to each 100 µl of cell suspension, and mixed gently.  Tubes were 
incubated at room temperature for 5 minutes.  A liquid nitrogen bath and a warm water 
bath were prepared in separate ice buckets.  Tubes containing lysozyme-treated cell 
suspensions were placed in liquid nitrogen bath until cells were frozen solid (~ 20 
seconds).  Then tubes were transferred to a flotation carrier and placed in a warm water 
bath until the suspension became fully liquid (~ 1 minute).  This freeze/thaw cycle was 
repeated for 10 times.  Benzonase
®
 (Novagen) was added to a final concentration of 
10 U/ml.  Cell lysates with Benzonase
®
 were incubated at room temperature for 
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10 minutes.  Cell debris was removed by a high spin in a tabletop microcentrifuge for 
10 minutes. 
For sonication lysis, bacterial were collected by centrifugation (4,500 g for 10 
minutes).  Cells were resuspended in 1× lysis buffer.  1 µl of 10 mg/ml lysozyme solution 
was added to each 100 µl of cell suspension, and mixed gently.  Tubes were incubated at 
room temperature for 5 minutes.  Tubes were then transferred to ice and allowed to cool 
down for 30 minutes.  Cells were sonicated on ice for 15 seconds followed by a 30 
second interval.  Sonication was repeated for 10 times.  Benzonase
®
 (Novagen) was 
added to a final concentration of 10 U/ml.  Cell lysates with Benzonase
®
 were incubated 
at room temperature for 10 minutes.  Cell debris was removed by a full speed spin in the 
tabletop microcentrifuge for 10 minutes. 
1.2 Yeast growth media and yeast cell lysis 
Yeast S. cerevisiae strains used in this study are listed in Table 1.  Yeast cells 
were grown at 30°C in YPD medium (1% yeast extract (w/v), 2% peptone (w/v), and 2% 
dextrose (w/v)) unless otherwise indicated.  Solid YPD medium was made with an 
additional final concentration of 2% agar (w/v).  Gentamicin was added to the medium to 
the indicated concentrations after autoclaving.  The growth of each culture was 
determined by direct cell counting with the aid of a hemacytometer.  Additional yeast 
growth media are presented as follows. 
Synthetic defined (SD) medium contains 1.7% yeast nitrogen base (w/o 
(NH4)2SO4) (w/v), 2% dextrose (w/v), and 0.5% (NH4)2SO4 (w/v).  Amino acid dropout 
mixtures were added after autoclaving.  Solid SD medium was made with an additional 
final concentration of 2% agar (w/v). 
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Minimal synthetic medium contains 0.1% (NH4)2SO4 (w/v), 0.05% MgSO4×2H2O 
(w/v), 0.087% KH2PO4 (w/v), 0.012% K2HPO4 (w/v), 0.01% NaCl (w/v), 0.01% 
CaCl2×2H2O (w/v), 0.83% succinic acid (w/v), 0.5% NaOH (w/v), 2% dextrose (w/v), 1% 
100× vitamins (v/v), and 0.1% 1000× trace elements (v/v).  To make the medium, NaOH 
was dissolve in water, which is about 80% of the desired volume.  Succinic acid was 
added followed by all salts and water.  Water was filled to 98.9% of the desired volume.  
After autoclaving and cooling of the medium to about 50°C, 100× vitamins (v/v) and 
1000× trace elements (v/v) were added.  0.1% of complete amino acids mixture dropouts 
(w/v) can be added as the nitrogen source.  Solid minimal synthetic medium was made 
with an additional final concentration of 2% agar (w/v). 
Nitrogen-free minimal synthetic medium:  0.05% MgSO4 (w/v), 0.087% KH2PO4 
(w/v), 0.012% K2HPO4 (w/v), 0.01% NaCl (w/v), 0.01% CaCl2×2H2O (w/v), 0.83% 
succinic acid (w/v), 0.5% NaOH (w/v), 2% dextrose (w/v), 1% 100× vitamins (v/v), and 
0.1% 1000× trace elements (v/v).  To make the medium, NaOH was dissolve in water, 
which was about 80% of the desired volume.  Succinic acid was added followed by all 
salts and water.  Water was added to 98.9% of the desired volume.  After autoclaving and 
cooling of the medium to about 50°C, 100× vitamins (v/v) and 1000× trace elements (v/v) 
were added.  Repressing nitrogen sources including ammonia, glutamine, glutamate and 
asparagine were added.  Derepressing nitrogen sources include urea, arginine, and proline 
can be added instead.  Solid minimal synthetic medium was made with an additional final 
concentration of 2% agar (w/v). 
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The 100× vitamin solution (100 ml final) contains 0.4 mg Biotin, 0.2 mg folic 
acid, 400 mg inositol, 40 mg niacin, 80 mg pantothenic acid, 20 mg pABA, 80 mg 
pyridoxine-hydrochloride, 20 mg riboflavin, and 80 mg thiamine. 
The 1000× trace elements solution (100 ml final) contained 100mg H3BO3, 100 
mg KI, 100 mg FeCl3×6H2O, 100 mg CuCl2×2H2O, 100 mg ZnCl2, and 100 mg 
MnCl2×4H2O. 
S. cerevisiae lysis buffer contains 0.15 M NaCl, 50 mM Tris-HCl (pH 7.5), 5 mM 
EDTA, 1% Triton X-100, and 1× Complete protease inhibitor cocktail (Roche, 
Indianapolis, IN) unless otherwise indicated.  Mechanical disruption (glass beads beating) 
method was applied to lyse yeast cells.  Yeast cells were collected by centrifugation at 
4,500 g for 10 minutes.  Cells were resuspended in 1× lysis buffer.  Cells were 
resuspended in 200 µl fresh 1× lysis buffer and transferred to a 1.5 ml Eppendorf tube.  
Acid-washed glass beads (Sigma G-8772) were added to the meniscus level of lysis 
buffer.  Tubes were cooled on ice for 10 minutes before being loaded onto the Mini-
BeadBeater-8
®
 (Biospec Products, Inc.).  One minute of full speed rapid agitation was 
performed.  Tubes were cooled on ice for 6 minutes.  The beating/cooling cycle was 
repeated two more times.  Cell debris was removed by centrifugation at 11,000 g, 4°C for 
40 minutes. 
1.3 Plasmid DNA isolation from bacteria 
Plasmid DNA was isolated from bacteria as follows by Qiagen Miniprep
®
.  
Briefly, a 5-10 ml bacteria overnight culture was spin down at 4,500 g for 10 minutes.  
Cells were resuspended in 1× lysis buffer and collected.  Cells were resuspended in 250 
μl Buffer P1 and transferred to a 1.5 ml Eppendorf tube.  250 μl of Buffer P2 was added 
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and mixed thoroughly by gently inverting the tube 4-6 times.  350 μl of Buffer N3 was 
added and mixed immediately and thoroughly by inverting the tube 4-6 times until the 
solution became cloudy.  Cell debris was removed by centrifuging the tubes for 10 min at 
11,000 g.  The supernatant was applied to a QIAprep
®
 spin column by pipetting.  After 
centrifuging for 30-60 seconds, flow-through was discarded.  The QIAprep
®
 spin column 
was washed by adding 0.5 ml of Buffer PB and centrifuging for 30-60 seconds.  Flow-
through was discarded.  QIAprep spin column was washed by adding 0.75 ml Buffer PE 
and centrifuging for 30-60 seconds.  Flow-through was discarded, and the column was 
centrifuged for an additional minute to remove residual wash buffer.  The QIAprep 
column was placed in a clean 1.5 ml microcentrifuge tube.  To elute DNA, 50 μl of 
Buffer EB (10 mM Tris-HCl, pH 8.5) or water (for the purpose of DNA sequencing) was 
added to the center of each QIAprep spin column.  The column was allowed to stand for 
one minute, and then centrifuged for one minute.  Flow-through was collected and 
measured in Nanodrop
®
 (Thermo Scientific) for the A260/A280 and A260/A230 ratios. 
1.4 Plasmid DNA isolation from yeast 
Plasmid DNA was isolated from yeast S. cerevisiae as described below.  5-10 ml 
of S. cerevisiae cells were cultured at 30°C to reach mid-log phase.  Cells were then 
harvested by centrifugation at 4,500 g for 5 minutes.  Cells were resuspended in ice cold 
ddH2O and respun.  Cells were resuspended in 250 μl of Buffer P1 and transferred to a 
1.5 ml Eppendorf tube.  Acid-washed glass beads (Sigma G-8772) were added to the 
meniscus level of lysis buffer.  The Eppendorf tube was cooled on ice for 10 minutes 
before sample was loaded onto the Mini-BeadBeater-8
®
 (Biospec Products, Inc.).  One 
minute of rapid agitation was performed.  The tube was cooled on ice for 6 minutes.  The 
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beating/cooling cycle was repeated 2 more times.  Cell debris was removed by 
centrifugation for 40 minutes at 11,000 g, 4°C.  The supernatant was transferred to a 
fresh 1.5 ml Eppendorf tube.  250 μl of lysis of Buffer P2 was added to the tube and 
mixed by inverting tube gently 4-6 times.  The tube was incubated at room temperature 
for 5 minutes.  350 μl of neutralization Buffer N3 was added to the tube and mixed 
immediately but gently by inverting 4-6 times.  After centrifuging the lysate for 10 
minutes at maximum speed in a tabletop microcentrifuge, supernatant was transferred to 
a QIAprep
®
 Spin Column by pipetting.  The flow-through was discarded after 
centrifuging for 30-60 seconds.  The QIAprep
®
 Spin Column was washed by adding 0.75 
ml of Buffer PE, followed by centrifugation for 30-60 seconds.  Flow-through was 
discarded and column was centrifuged for an additional minute to remove residual wash 
buffer.  The QIAprep Spin Column was placed in a clean 1.5 ml Eppendorf tube.  To 
elute DNA, 25 μl of Buffer EB (10 mM Tris-HCl, pH 8.5) or water (for the purpose of 
DNA sequencing) was added to the center of each QIAprep
®
 Spin Column.  The column 
was allowed to stand for one minute, and was then centrifuged for one minute.  The flow-
through was collected and the O.D. was measured in a Nanodrop
®
 (Thermo Scientific) 
for the A260/A280 (1.8 for DNA, 2.0 for RNA) and A260/A230 (should be very close to 2.0, 
otherwise consider contamination) ratio. 
1.5 Bradford assay 
Six standard solutions which contain 0, 1 µl, 2 µl, 4 µl, 8 µl or 10 µl of 1.4 mg/ml 
bovine serum albumin (BSA) were prepared.  ddH2O was added to each solution to a 
final volume of 800 µl.  200 µl of 1× Bradford Dye was added to each solution and 
mixed well.  The absorbance at 595 nm was measured for each solution twice.  A graph 
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plotting absorbance at 595 nm versus protein concentration was created.  The graph was 
then used as a protein standard curve for further protein samples (Bradford, 1976). 
The protein concentration of a sample was determined from its absorbance, using 
the standard curve to find the concentration of the standard which had the same 
absorbance as the sample.  The protein concentration equation from the curve which was 
used in this study is:  sample protein concentration = A595nm ÷ (n ×0.068 µg/µl) (n: n µl of 
samples were added to the 1 ml solution). 
2   Transformations 
2.1 Bacterial transformation 
Bacteria cells are considered competent when the cells are able to take up DNA 
from the environment.  To prepare competent bacteria cells, early log-phase growing 
bacteria were washed with CaCl2, concentrated by centrifugation, and then resuspended 
in a small volume of CaCl2.  By doing this, the cell membrane of chemically competent 
bacteria is more permeable to DNA (Dagert & Ehrlich, 1979).  The procedure is as 
follows. 
A 100 µl aliquot of frozen E. coli DH5α cells was taken from -80°C and 
inoculated into 50 ml of sterile LB broth.  Antibiotics were not added since these cells do 
not have an antibiotic resistance-marker containing plasmid in them.  Cells were grown at 
37°C with shaking until they reached an OD600nm of 0.3 to 0.4 (1 cm pathlength).  Cells 
were collected by centrifugation at 5,000 g for 10 minutes at 4°C.  100 mM CaCl2 and 
100 mM MgCl2 solutions were cooled on ice.  The bacteria cell pellet was gently 
resuspended on ice in 12.5 ml (1/4 of the initiated volume) of ice cold MgCl2, taking 3 to 
5 minutes for this procedure.  Cells were collected by centrifugation at 4,000 g for 10 
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minutes.  The bacteria cell pellet was resuspended on ice in 2.5 ml (1/20 of the initial 
volume) of ice cold CaCl2, followed by an additional 22.5 ml (9/20 of the initial volume) 
of CaCl2.  The suspension was kept on ice for at least 20 minutes.  Cells were collected 
by centrifugation at 4,000 g for 10 minutes and were resuspended in 1 ml (1/50 of the 
initial volume) of ice cold sterile 85 mM CaCl2 in 15% glycerol (w/v).  The competent 
cells were then ready for use. 
Temperature changes affect competent cells greatly and reduce their efficiency 
over time.  In the laboratory, we always prepare and store these cells in small aliquots to 
avoid free/thaw effects.  It is recommended to dispense competent cells in 100 µl aliquots 
and freeze cells at -80°C.  Always thaw and keep cells on ice prior to use (Chung, 
Niemela, & Miller, 1989). 
DNA was added to an aliquot of competent cells, and then incubated on ice for 45 
minutes.  The cell-DNA mixture sample was taken (still in the ice bucket) to a 42°C 
waterbath and heat shocked for 45 seconds.  The temperature change in this heat-shock 
step should be very sudden, i.e., from 0°C directly to 42°C.  The heat shock opens 
transient pores in the bacteria due to the destabilizing effect of the CaCl2.  The CaCl2 in 
the transfection solution helps to bring the DNA close to the cell membrane.  After 45 
seconds at 42°C, the cells were plunged into an ice bath (from 42°C directly to 0°C).  It is 
important for the sample to go from 42°C water back into an ice bath immediately after 
the heat shock.  Cells were incubated on ice for 2 minutes to allow the transient pores in 
the bacteria to close, trapping the DNA inside the cells.  950 µl of LB medium was added 
to the transformation mixture without antibiotics.  Cells were then cultured at 37°C for 
1 hour with shaking.  During this time the antibiotic resistance genes are expressed, and 
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the number of colonies will be increased due to bacterial division.  10-100 µl of the 
culture was spread onto solid selectable media and incubated at 37°C for 8 hours (Cohen, 
Chang, & Hsu, 1972) or overnight until colonies appear. 
2.2 Yeast transformation 
Yeast cells were cultured in 100 ml of YPD medium at 30°C with shaking.  At 
mid-log phase (8×10
6 
cells/ml), the cells were harvested by centrifugation at 4,000 g for 5 
minutes, washed once with TE buffer (pH 8.0), and resuspended in the same buffer to a 
final concentration of 2 x 10
8
 cells/ml.   
A 0.5 ml portion of the cell suspension was transferred to a test tube, and an equal 
volume of 0.2 M Li
+
 (LiCl or Lithium acetate) was added.  After one hour of incubation 
at 30°C with shaking, 0.1 ml of the cell suspension was transferred to a 1.8 ml Eppendorf 
tube.  25 µl of plasmid DNA solution (670 µg/ml) was added.  The incubation continued 
for another 30 minutes at 30°C.  An equal volume of sterilized 70% polyethylene glycol 
(PEG)-3250 was added and mixed thoroughly on a Vortex mixer.  After standing for 1 
hour at 30°C, the 1.7 ml Eppendorf tube was immersed into a 42°C water bath and 
incubated for 5 minutes.  The cells were cooled at room temperature, washed twice with 
room temperature ddH2O, and resuspended again in 1.0 ml of ddH2O.   
The transformed cells were finally spread on selective media plates and incubated 
for at least 48 hours until the transformed strains formed colonies (Ito et al., 1983; 
Schiestl & Gietz, 1989). 
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3   SDS-PAGE and Western Blotting 
3.1 SDS-PAGE 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis, SDS-PAGE, is a 
technique which is widely used in biochemistry to separate proteins according to their 
molecular mass.  7% SDS-PAGE gels were used to separate proteins from 75 kDa to 250 
kDa, 10% SDS-PAGE gels were used to separate proteins from 30 kDa to 100 kDa, and 
12% SDS-PAGE gels were used to separate proteins from 15 kDa to 70 kDa, 
respectively. 
The 7% SDS-PAGE running gel was made with: 15.3 ml of H2O, 7.5 ml of 1.5 M 
Tris-HCl (pH 8.8), 0.15 ml of 20% (w/v) SDS, 6.9 ml of acrylamide/bis-acrylamide 
(30%/0.8% w/v), 0.15 ml of 10% (w/v) ammonium persulfate (APS), and 0.02 ml of 
TEMED, which was added under a hood. 
The 10% SDS running gel was made with: 12.3 ml of H2O, 7.5 ml of 1.5 M Tris-
HCl (pH 8.8), 0.15 ml of 20% (w/v) SDS, 9.9 ml of acrylamide/bis-acrylamide 
(30%/0.8% w/v), 0.15 ml of 10% (w/v) ammonium persulfate (APS), and 0.02 ml of 
TEMED, which was added under a hood. 
The 12% SDS-PAGE running gel was made with: 10.2 ml of H2O, 7.5 ml of 1.5 
M Tris-HCl (pH 8.8), 0.15 ml of 20% (w/v) SDS, 12 ml of acrylamide/bis-acrylamide 
(30%/0.8% w/v), 0.15 ml of 10% (w/v) ammonium persulfate (APS), and 0.02 ml of 
TEMED, which was added under a hood. 
The stacking gel was made with: 3.075 ml of H2O, 1.25 ml of 0.5 M Tris-HCl (pH 
6.8), 0.025 ml of 20% (w/v) SDS, 0.67 ml of acrylamide/bis-acrylamide (30%/0.8% w/v), 
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0.025 ml of 10% (w/v) ammonium persulfate (APS), and 0.005 ml of TEMED, which 
was added under a hood. 
The cells were cultured to the desired cell density and lysed with mechanical lysis 
(glass bead beating).  The amount of protein loaded in each lane was calculated based on 
the total protein concentration determined by Bradford assay.  Normally, 12 µg of protein 
from a whole cell lysate or 2 µg of a pre-purified protein was loaded in each lane for a 
1.5 mm Mini-Protein Gel (Biorad, CA).  The loading buffer was added to each protein 
sample in a 1:4 ratio (v/v).  The maximum loading capacity of the 1.5 mm thick Biorad 
Mini-Protein gels were 25 µl in each well.  For the denatured SDS-PAGE samples, the 
protein and loading buffer mixture was heated at 80ºC for 5 minutes before being 
collected and loaded onto the SDS-PAGE gel.   
SDS-PAGE gels were run at 60V through the stacking portion of the gel (about 20 
minutes) and then at 110V through the resolving portion (about 1.5 to 2 hours) until the 
dye front reached the bottom of the gel. 
3.2 Western Blotting 
The SDS-PAGE gel was then transferred (wet transfer) to a nitrocellulose 
membrane at a constant voltage of 28V for 2 hours (room temperature) or 20V overnight 
(4ºC).  If the desired protein was of a large molecular weight (> 100 kDa), overnight 
transfer was always used. 
The membrane was rinsed in KPBS-T buffer for 5 minutes before being blocked 
in KPBS-T buffer containing 5% non-fat dry milk for 1 hour at room temperature.  The 
primary antibody was added to KPBS-T buffer containing 5% milk and the membrane 
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was incubated for 2 more hours at room temperature or overnight at 4ºC.  The primary 
antibody was diluted to 1:1000 or 1:2000 in this step. 
The membrane was rinsed in KPBS-T buffer 3 times (10 minutes each time).  
Then the membrane was incubated with secondary antibody which had been diluted in 
5% milk in KPBS-T buffer.  The incubation lasted 1 hour at room temperature.  The 
secondary antibody was already diluted to 1:5000 or 1:10000 in this step. 
The membrane was washed in KPBS-T buffer 3 times (10 minutes each time).  If 
the secondary antibody was HRP-conjugated, Amersham ECL detection reagent was 
applied to the membrane. 
Finally, the membrane was exposed to the autoradiograph film for the desired 
amount of time (from 2 seconds to overnight). 
3.3 Coomassie Blue Staining and Silver Staining 
The Coomassie blue staining solution contained 2.5 g Coomassie brilliant blue R-
250, 450 ml of methanol, 100 ml of glacial acetic acid, adjusted with water to 1 liter. 
The Coomassie blue destaining solution contained 0.0075% (v/v) of glacial acetic 
acid and 10% (v/v) of ethanol in water. 
Silver staining method was modified from the Witzmann laboratory‟s protocol 
(Lai et al., 2009).  Only ddH2O was used in making all solutions and wash buffers.  Clean 
glass trays were used in every step.  SDS-PAGE gels were fixed for at least 30 minutes in 
a solution of 50% methanol, 10% acetic acid (overnight is fine).  SDS-PAGE gels were 
washed twice for 15 minutes each in a solution of 5% methanol and 1% acetic acid.  
SDS-PAGE gels were washed three times with water, 10 minutes each.  SDS-PAGE gels 
were sensitized by treating with 0.2 g/L sodium thiosulfate solution for 90 seconds 
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followed by three 30 second rinses with water.  SDS-PAGE gels were incubated in silver 
nitrate solution (2g/L) for 45 minutes.  SDS-PAGE gels were rinsed three times in water, 
20 seconds each.  SDS-PAGE gels were developed using a solution with 60g/L of 
potassium carbonate, 0.05% (v/v) 37% formaldehyde, and 0.02g/L sodium thiosulfate.  
Developing usually takes ~ 5 minutes.  The key is to stop developing process before 
background gets too dark.  SDS-PAGE gels were stopped with 6% (v/v) acetic acid for 30 
minutes.  SDS-PAGE gels were rinsed with water before scanning. 
4   Dual-luciferase Assay 
4.1 Plasmids sequencing 
Plasmids pYDL-control, pYDL-LA, and pYDL-TY1 were sequenced by 
automated dye-terminator sequencing.  The primer designed to amplify the junction 
between the ADH1 promoter and the Renilla luciferase gene was as follows: 5‟-
TTGTTCCAGAGCTGATGAGG.  The primer designed to amplify the junction between 
the Renilla luciferase gene and the Firefly luciferase gene was as follows: 5‟-
CATGGCCTCGTGAAATCC.  The primer designed to amplify the junction between the 
Firefly luciferase gene and the CYC1 terminator was as follows: 5‟-
CCCGCTGAATTGGAATCG. 
4.2 Luciferase Assay System
®
 
Yeast stains harboring pYDL series of plasmids were inoculated into 5 ml of (-) 
uracil liquid medium at an OD595 = 0.7.  Cells were harvested by centrifugation at 
4,000 g for 10 minutes.  Cells were resuspended in 1 ml of ice cold lysis buffer and 
washed once.  The cells were resuspended in 0.3 ml of lysis buffer and lysed with the 
glass beads beating method.  The Bradford assay was applied to determine protein 
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concentration.  Luciferase activities were determined by using 5 µl of the lysate with the 
Luciferase Assay System
®
 (Promega, Madison, WI). 
The raw data readings were collected from a Monolight
®
 2010 Luminometer 
(Analytical Luminescence Laboratory).  In each luminometer tube, 100 µl of LARII 
(from Dual-Luciferase
®
 Reporter Assay System, Promega, Madison, WI) was 
predispensed.  The luminometer was programmed.  5 µl of the cell lysate was transferred 
and mixed with LARII by pipetting/stirring.  The firefly luciferase activity was measured 
in the luminometer.  100 µl of Stop and Glo Reagent was dispensed and mixed by 
pipetting/stirring.  The Renilla luciferase activity was measured similarly (De Wet et al., 
1985).  Each sample was measured in triplicate. 
5   GTP-bound ARF1-TAP Pull-down Assay 
Plasmid pAB382 was kindly provided by Dr. P. Scott (University of Minnesota 
Medical School) (Scott et al., 2004).  The gene encoding Gga2 (amino acid 1-326) was 
inserted into vector pGEX-5X-2 (Amersham Pharmacia, NJ) between the BamHI and 
XhoI sites.  The plasmid encoded a fusion protein containing Gga2 in-frame with an 
amino terminal GST. 
BL21 (DE3) bacterial cells transformed with pAB382 were cultured at 37°C in 
10 ml LB medium containing ampicillin (150 µg/ml) for 12-16 hours to reach 
confluence.  This preculture was then diluted to 500 ml with fresh LB medium containing 
ampicillin (150 µg/ml) and also cultured at 37°C. 
When the culture reached an OD600 of 0.6~0.8, isopropyl β-D-thiogalactoside 
(IPTG) was added to the culture medium to a final concentration of 0.8 mM, and the cells 
were incubated at 37°C for an additional 5 hours.  Cells were collected by centrifugation 
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(10 minutes at 4500 g, 4°C).  Cell pellets were resuspended in lysis buffer and repelleted; 
then washed once and resuspended in 7 ml of ice-cold lysis buffer containing 20 mM 
Tris-HCl (pH 7.4), 100 mM NaCl, 0.1% (w/v) Triton X-100, and 1× complete protease 
inhibitors (Roche, Indianapolis, IN).  Cells were sonicated on ice 20 times for 15 seconds 
at 30 second intervals.  The homogenate was then centrifuged (60 minutes at 15,000 g, 
4°C) and the protein concentration of the supernatant was determined by Bradford assay. 
Ten MicroSpin GST Purification Modules (Amersham Pharmacia, NJ) with 50 µl 
bed volume of Glutathione Sepharose 4B were prewashed with 300µl of lysis buffer.  
174 µg of protein from the supernatant was gently mixed with each MicroSpin column 
and incubated at 4°C for 50 minutes to ensure optimal binding of GST-Gga2p
1-326
 to the 
Glutathione Sepharose 4B matrix.  After incubation, the flow-through of each MicroSpin 
column and four subsequent washes with 150 µl lysis buffer were discarded.  200 µg 
(adjusted to a final volume of 250 µl) of yeast ARF1-TAP strain whole cell lysate 
prepared from yeast cells grown to different cell densities and in the absence or presence 
of gentamicin were added to the MicroSpin columns and incubated at 4°C for 30 minutes.  
The flow-through of each MicroSpin column and four consecutive washes with 150 µl 
lysis buffer were discarded.  40 µl of elution buffer (10 mM glutathione, 50 mM Tris-HCl 
pH 8.0) was added and final spin elutions were collected for SDS-PAGE and Western 
Blot analysis. 
6   Spot Dilution Assay 
S. cerevisiae strains were inoculated at 30°C in liquid YPD medium unless 
otherwise indicated.  Cell number was counted using a microscope and a hemacytometer 
at mid-log phase (8×10
6
 ~ 2×10
7
 cells/ml).  Based on the cell counts, 4 µL of several cell 
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dilutions were placed side by side onto solid YPD media in the absence or presence of 
gentamicin.  In brief, 4 µL of dilutions containing 10,000 cells, 1,000 cells, 100 cells, or 
10 cells (or other cell numbers as indicated) were plated.  Plate images were taken after 
an incubation at room temperature (or 30°C as indicated) for approximately 2-3 days. 
7   Carboxypeptidase Y Processing Assay 
Wild-type or mutant S. cerevisiae strains were inoculated at their permissive 
temperature to early-log phase (5×10
6
 cells/ml) before gentamicin (to a final 
concentration of 500 µg/ml) was added to the medium.  After 0, 4 or 8 hours of additional 
incubation at their permissive temperature, aliquots of cells were removed, lysed and 
prepared for SDS-PAGE and Western Blot analysis using anti-CPY (Molecular Probes, 
Invitrogen) as the primary antibody. 
8   Gentamicin-Sepharose 4B Affinity Binding Assay 
CNBr-activated sepharose 4B (2 g; GE healthcare, NJ) was thoroughly swollen in 
10 ml of 1mM HCl (to a final volume of 7 ml) and washed with 400 ml of 1 mM HCl in 
several aliquots followed by an additional wash with 20 ml of coupling buffer (0.1 M 
NaCO3 pH 8.3, 0.5 M NaCl).  The resin was separated into a control resin group and 
gentamicin-binding resin group.  The control resin was mixed with 10 ml of the coupling 
buffer and incubated at 4°C overnight with gentle rotation.  The gentamicin-binding resin 
was mixed with 10 ml of gentamicin coupling buffer (10 mM gentamicin, 0.1 M NaHCO3 
pH 8.3, 0.5 M NaCl) and incubated under the same conditions as the control resin.  For 
the gentamicin-binding resin, the excess gentamicin was removed by washing the resin 
with 40 ml of the coupling buffer.  The remaining CNBr-activated groups on both resins 
were inactivated by incubation with blocking buffer (0.2 M glycine pH 8.0, 1% bovine 
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serum albumin) at 4°C overnight with gentle agitation.  The resins were then washed with 
three cycles of alternating pH (0.1 M acetic acid/sodium acetate (pH 4.0) containing 0.5 
M NaCl and 0.1 M Tris-HCl (pH 8.0) containing 0.5 M NaCl).  Each resin was 
equilibrated in PBS (0.05 M NaH2PO4, 0.05 M Na2HPO4, 0.2 M NaCl pH 7.4) before use. 
400 µg of yeast whole cell lysate (adjusted to a final volume of 2 ml) from mid-
log phase yeast ARF1-TAP strain was added to 1 ml of either the control resin or the 
gentamicin-binding resin and incubated at 4°C for 2 hours with gentle agitation.  Each 
resin was washed four times with 10 ml of PBS buffer before a final elution with 6 ml 
elution buffer (0.05 M NaH2PO4, 0.05 M Na2HPO4, 1 M NaCl pH 7.4, 10 mM 
gentamicin) which was concentrated to 40 µl using a Vivaspin 500 column (MWCO 
5kDa, GE Healthcare).  The flow-through of the four washes and concentrated elution 
were collected for SDS-PAGE and Western Blotting analysis. 
9   Mass Spectrometry Analysis of Gentamicin Binding Proteins Assay 
A single colony of yeast strain BY4741 was inoculated overnight in liquid YPD at 
30ºC.  The overnight culture was then diluted to 1×10
6
 cells/ml by liquid YPD in the 
presence or absence of gentamicin (500 μg/ml).  The subcultures were incubated 
overnight again at 30ºC.  Both subcultures were diluted to 2×10
6
 cells/ml in liquid YPD 
in the presence or absence of gentamicin (500 μg/ml) on the next day, followed by an 
additional incubation of 5 hours until the subcultures reached mid-log growth phase with 
a cell density of 1×10
7
 cells/ml.  Cells were harvested by centrifugation and washed once 
with ice cold lysis buffer.  Mechanical lysis (with glass beads beating) of the cells was 
performed.  The supernatants of the cell lysates were collected for gentamicin affinity 
binding column and protein concentrations were determined by the Bradford assay. 
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A yeast lysate which contained 0.8 mg of protein was applied to either the 
gentamicin-affinity resin (1 ml) or the negative control resin (1 ml), and both resins were 
incubated at 4ºC overnight with gentle agitation.  The columns were washed with 15 ml 
of washing buffer (0.2 M NaCl, 1.3 mM Ca
2+
, 20 mM Tris-HCl pH7.6, 0.5 mM 
deoxycholate) before being eluted by 10 ml elution buffer (1 M NaCl, 10 mM gentamicin, 
20 mM Tris-HCl pH 7.6, 0.5 mM deoxycholate).  The elution was collected for mass 
spectrometric protein analysis. 
The elution (10 ml) was concentrated by Vivaspin 500
® 3 kDa MWCO (GE 
Healthcare) to a final volume of 500 μl.  Proteins were reduced with dithiothreitol (DTT, 
to a final concentration of 10 mM) at 37°C for 2 hours.  After the samples were cooled to 
room temperature, iodoacetamide (to a final concentration of 50 mM) was added and 
samples were placed at room temperature for an additional 30 minutes in the dark.  The 
samples were dialyzed against 10 mM ammonium bicarbonate using a Vivaspin 500
® 3 
kDa MWCO until the NaCl concentration was less than 0.1 mM.  Trypsin was added at a 
1:50 ratio (trypsin to protein ratio).  Samples were digested overnight at 37°C. 
The digested samples were analyzed by a Thermo-Finnigan linear ion-trap (LTQ) 
mass spectrometer coupled with a Surveyor autosampler (Thermo Scientific) and MS 
HPLC system.  Each sample was injected twice onto a C18 microbore RP column 
(Zorbax SB-C18, 1.0 mm ×150 mm) at a flow rate of 50 μl/minute.  The mobile phase A, 
mobile phase B, and mobile phase C were 0.1% formic acid in water, 50% acetone with 
0.1% formic acid in water, and 80% acetone with 0.1% formic acid in water, 
respectively.  The gradient elution profile was as follows: 10% B (90% A) for 5 minutes; 
10-95% B (90-5% A) for 120 minutes; 100% C for 10 minutes; and 10% B (90% A) for 
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12 minutes.  An initial parent mass scan of 400-2000 m/z was followed by 3 additional 
MS/MS scans of 200-2000 m/z with 35% of the normalized collision energy.  Dynamic 
exclusion settings were as follows: the repeat count, 2; the repeat duration, 30 seconds; 
the exclusion duration, 120 seconds; the exclusion mass width, 0.75 m/z (low) and 2.0 
m/z (high) (Lai et al., 2009). 
The acquired data were searched against the modified yeast database created by 
M. Goebl from the SGD database using the SEQUEST (v. 28 rev. 12, Thermo Scientific) 
algorithms in Bioworks (v. 3.3, Thermo Scientific).  General parameters were set as Lai 
and colleagues (Lai et al., 2009).  The candidate peptides and proteins were validated by 
PeptideProphet (http://peptideprophet.sourceforge.net/) and ProteinProphet in the Trans-
Proteomic pipeline (TPP, v. 3.3.0, Seattle Proteome Center, NHLBI Proteomics Center at 
the Institute for Systems Biology). 
Biological replicates (n = 4) were applied for gentamicin-affinity binding resin 
and negative control resin. 
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RESULTS 
CHAPTER 1: ARF1 PATHWAY IN THE GENTAMICIN RESPONSE OF 
SACCHAROMYCES CEREVISIAE 
1   Gentamicin Sensitivity of arf1
ts 
arf1∆ arf2∆ Strains 
The arf1
ts 
arf1∆ arf2∆ strains (gifts from Dr. Ken Sato, Molecular Membrane 
Biology Lab, RIKEN, Japan) used in this study are listed in Table 1.  In this study, we 
examined whether the cells with reduced Arf1 activity were hypersensitive to gentamicin.  
Since arf1∆ arf2∆ double deletion cells are inviable, temperature sensitive (ts) alleles of 
ARF1, arf1-11, arf1-16 or arf1-18, were integrated at the ADE2 locus in the
 
chromosome 
(Yahara et al., 2001).  The non-permissive temperature of arf1-11
 
arf1∆ arf2∆ and arf1-
16
 
arf1∆ arf2∆ strains is over 30ºC.  The non-permissive temperature of arf1-18 arf1∆ 
arf2∆ strain is over 37ºC (Yahara et al., 2001). 
The arf1-11 arf1∆ arf2∆, arf1-16 arf1∆ arf2∆ and arf1-18 arf1∆ arf2∆ strains are 
representatives of three intragenic complementation groups (Yahara et al., 2001).  The 
arf1-11 arf1∆ arf2∆ strain encodes an Arf1 with the following point mutations K38T, 
E132D, and L173S.  None of these amino acid residues lies within a known Arf1 
functional domain.  E132D and K38T lie very close to two separated so-called Guanine 
Specific Regions, which can bind and stabilize guanine nucleotides.  The phenotypes of 
the arf1-11 arf1∆ arf2∆ strain include very clear defects in ER-to-Golgi transport, which 
are due to the
 
impaired recycling of ER-resident proteins from Golgi-to-ER retrograde 
trafficking (Yahara et al., 2001). 
The arf1-16 arf1∆ arf2∆ strain encodes an Arf1 with the following point 
mutations D129E and E41V.  In fact, D129 lies in a highly conserved domain 
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(N126K127X128D129, where X indicates any amino acid), which is called the G-4 Region of 
all the small GTPases (Bourne et al., 1991).  More specifically, eukaryotes have a 
conserved NKQD as their G-4 region in all the Arf proteins.  The G-4 region plays a key 
role in the binding and stabilization of guanine nucleotides.  The diploid strain that 
carries one allele of the triple deletion (K127, D129, E132) has a dominant lethal 
phenotype (Click et al., 2002).  The other mutation site of the arf1-16 arf1∆ arf2∆ strain, 
E41, lies in the Switch1 Region (E41VITTIPTIGFNVET), which is also recognized as 
one of the Sec7-binding domains and is highly conserved among all eukaryotic species 
(Mossessova et al., 1998).  Actually, the Switch1 Region will undergo major 
conformational changes upon GTP binding and can bind to downstream effectors.  For 
this reason, the Switch1 Region is also called the effector domain.  The phenotypes of 
arf1-16 arf1∆ arf2∆ include defects in both Golgi-to-ER and ER-to-Golgi transport 
(Yahara et al., 2001). 
The arf1-18 arf1∆ arf2∆ strain has an Arf1 point mutation at H80P.  This point 
mutation lies in another Sec7-binding domain, GGQDRIRSLWRH80, which is also 
recognized as the Switch2 Region (Mossessova et al., 1998).  The intracellular transport 
remains normal in the arf1-18 arf1∆ arf2∆ strain.  But cells from the arf1-18 arf1∆ arf2∆ 
strain have large stacks of the Golgi apparatus and numerous small vesicles inexplicably 
scattered throughout the cytoplasm for unknown reasons (Yahara et al., 2001). 
As expected, our experiments found that at permissive temperature (room 
temperature), all of the arf1
ts 
arf1∆ arf2∆ strains and the  ARF1 arf2∆ strain had wild-
type growth on YPD medium plate.  However, at 37°C, all of the arf1
ts 
arf1∆ arf2∆ 
strains exhibited temperature sensitive growth (Figure 4A) on YPD medium. 
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Spot dilution assays of the ARF1 arf2∆ and arf1ts arf1∆ arf2∆ strains at 
permissive temperature (room temperature) are shown in Figure 4B.  All strains grew 
well on YPD plates in the absence of gentamicin.  For each strain, a serial dilution was 
applied to a YPD plate ranging from 1×10
7
cells/ml to 1.3×10
6 
cells/ml.  Although ARF1 
arf2∆ cells were relatively unaffected by gentamicin, all of the arf1ts arf1∆ arf2∆ cells 
were hypersensitive to gentamicin.  The hypersensitivity generated by the three alleles 
was quite variable: arf1-11 arf1∆ arf2∆ and arf1-16 arf1∆ arf2∆ showed growth defects 
at a relatively low gentamicin concentration (100 μg/ml and 250 μg/ml); however, arf1-
18 only showed mild growth defects at a much higher gentamicin concentration (500 
μg/ml). 
We also observed that single deletion strains of arf1∆ and arf2∆ were not 
sensitive to up to 500 µg/ml of gentamicin on the YPD medium plate. 
From the literature, we knew that Arf1 and Arf2 are functionally interchangeable 
(Stearns et al., 1990).  And in our experiments, we clearly show that in arf2∆ strains, the 
loss of Arf1 protein function can cause yeast cells to become hypersensitive to 
gentamicin. 
These results suggest that arf2∆ cells with impaired Arf1 function are 
hypersensitive to gentamicin, and Arf1 is required for gentamicin resistance in 
S. cerevisiae.  Next, we examined if gentamicin, by itself, can affect the intracellular 
protein expression level of Arf1, or affect the GTP-bound Arf1 to GDP-bound Arf1 ratio 
in yeast S. cerevisiae. 
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2   Change in GTP-bound Arf1 Protein Level during Different Cell Growth Phases 
The Gga (γ-ear adaptin homology Golgi associated Arf-binding protein) family 
members are ubiquitous Golgi-localized clathrin-coated cargo adaptors (Puertollano 
et al., 2001).  As mentioned previously, Gga2 protein binds exclusively to the GTP-
bound form of Arf1 (Yoon et al., 2005). 
In our experiments, we utilized yeast whole cell extracts to measure total Arf1 
protein expression levels in different cell growth phases, and utilized a GST-labeled 
truncated yeast Gga family protein Gga2
1-326
 to obtain a relative measurement of GTP-
bound Arf1, also in different cell growth phases (Boman et al., 2002).  The GST-GGA2
1-
326
 carrying plasmid pAB382 (Table 1) (kindly provided by Dr. P. Scott, University of 
Minnesota Medical School) (Scott et al., 2004) was transformed into bacteria BL21 
(DE3) strain.  After IPTG (0.3 mM) induction, GST-Gga2
1-326
 protein was purified and 
later bound to GST-sepharose as described in Materials and Methods.  Since the 
sepharose-bound GST-Gga2
1-326
 only binds to GTP-bound Arf1, the Arf1 eluted from the 
sepharose by 10 mM glutathione is only the GTP-bound Arf1 in the whole cell extracts. 
We used the yeast S. cerevisiae Arf1-TAP (MATa his3Δ1 leu2Δ0 met15Δ0 
ura3Δ0 ARF1::TAP-HIS3MX6, Table 1) strain in this study because of the easy detection 
of Arf1 by Anti-TAP antibody (CAB1001, Open Biosystems) during Western Blotting.  
Cells of this Arf1-TAP strain were cultured in YPD medium or YPD + 500µg/ml 
gentamicin medium to early-log growth phase (cell density 5×10
6
 cells/ml), mid-log 
growth phase (cell density 1×10
7
 cells/ml and 2.5×10
7
 cells/ml), late-log growth phase 
(cell density 5×10
7
 cells/ml) or stationary phase (1×10
8
 cells/ml) before being harvested 
(Figure 5). 
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Firstly, we noticed that total Arf1 protein expression level remained constant, 
regardless of the absence or presence of gentamicin (500 μg/ml) in the media or the 
different growth phases of the cells (Figure 5B). 
Secondly, the effect of gentamicin on GTP-bound Arf1 varied in the different 
growth phases (Figure 5A and 5C).  When cells were in early-log growth phase and were 
to enter mid-log growth phase (cell density 5x10
6
 cells/ml and 1×10
7
 cells/ml, Figure 
5A), the relative abundance of GTP-bound Arf1 was dramatically reduced in cells 
inoculated with gentamicin (500 μg/ml).  However, when cells were in mid-log growth 
phase and late-log growth phase (cell density 2.5x10
7
 and 5x10
7
 cells/ml, Figure 5A), 
there was no detectable difference in GTP-bound Arf1 levels in cells grown in the 
presence or absence of gentamicin.  Finally, when cells were in stationary phase (cell 
density 1×10
8
 cells/ml), gentamicin caused an increase in the relative abundance of the 
GTP-bound Arf1 (Figure 5A and 5C). 
In conclusion, gentamicin (500 μg/ml) can affect the level of GTP-bound Arf1 in 
a cell growth phase-dependent manner, even though total Arf1 protein expression levels 
in yeast S. cerevisiae is not affected by gentamicin (500 μg/ml).  At this point, it remains 
unclear whether any Arf1-GEF or Arf1-GAP function is affected by gentamicin.  But our 
other studies suggest some possibilities which are presented later in this Chapter. 
These results led us to investigate the gentamicin hypersensitivity of each 
gentamicin sensitive mutation strain in different growth phases. 
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3   Gentamicin Hypersensitivity of Gene Deletion Strains in Different Growth 
Phases 
It has been reported that the loss of SAC1, VPS52, VPS16, ZUO1, or VPS45 can 
result in gentamicin hypersensitivity in yeast S. cerevisiae (Wagner et al., 2006).  In this 
study, we compared gentamicin sensitivity of all these single deletion strains, but in 
different growth phases, early-log growth phase, mid-log growth phase, and late-log 
growth phase.  Cells of different strains from different growth phases were placed on 
YPD plates in the absence or presence of 50 or 100 µg/ml of gentamicin (Figure 6). 
As a result, the sac1∆ strain showed gentamicin hypersensitivity on 50 µg/ml 
gentamicin plates.  The growth phase affected gentamicin hypersensitivity only 
marginally.  Compared with the previous liquid culture data,  a 24-30 hours culture of the 
sac1∆ strain shows 80% growth inhibition in 50 µg/ml gentamicin + YPD medium 
(Wagner et al., 2006).  The results suggest that S. cerevisiae cells are more sensitive to 
gentamicin in liquid broth. 
The vps52∆ strain was sensitive to 50 µg/ml gentamicin and was more sensitive at 
mid-log phase or late-log phase on 100 µg/ml gentamicin plates (Figure 6).  Compared 
with the previous liquid culture data, a 24-30 hour culture of the vps52∆ strain shows 
clear growth inhibition (over 90%) in 50 µg/ml gentamicin + YPD medium (Wagner 
et al., 2006). 
The vps16∆ strain was sensitive to 100 µg/ml gentamicin.  Cells were more 
sensitive at late-log growth phase and mid-log growth phase than early-log growth phase 
(Figure 6).  At a lower gentamicin concentration (50 µg/ml), growth inhibition was not 
observed on plates (Figure 6).  Compared with the previous liquid culture data, a 24-30 
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hour culture of the vps16∆ strains showed growth inhibition (over 90%) in 50 µg/ml 
gentamicin + YPD medium (Wagner et al., 2006). 
The zuo1∆ strain was sensitive to 50 µg/ml gentamicin and was more sensitive at 
late-log growth phase.  Compared with the previous liquid culture data, a 24-30 hour 
culture of the zuo1∆ strain showed over 90% inhibition in 50 µg/ml gentamicin + YPD 
medium (Wagner et al., 2006). 
The vps45∆ strain does not show growth inhibition in any growth phase in 
gentamicin as high as 500 µg/ml (data not shown).  Compared with the previous liquid 
culture data, a 24-30 hour culture of the vps45∆ strain showed 50% growth inhibition in 
50 µg/ml gentamicin + YPD medium, and a 90% growth inhibition in 500 µg/ml 
gentamicin + YPD medium (Wagner et al., 2006).  But the growth inhibition was not 
detected on plates. 
To summarize, cells from sac1∆, vps52∆, vps16∆, and zuo1∆ strains have slightly 
different sensitivities to gentamicin in different cell growth phases (Figure 6).  But 
overall gentamicin sensitivity effect is not highly related to the cells initial growth phases. 
4   Impaired Arf1 Activity and Gentamicin Hypersensitivity 
As mentioned previously, Arf1 is a small GTPase and GTP-bound Arf1 plays an 
essential role in the formation of transport vesicles.  In fact, the switching between GTP-
bound and the GDP-bound form Arf1 is tightly regulated by Arf-GEFs and Arf-GAPs.  
Here, we further investigate whether gentamicin has an effect on any Arf-GEFs or Arf-
GAPs. 
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4.1 The loss of Arf-GEF function and gentamicin hypersensitivity 
Sec7, Gea1 and Gea2, and Syt1 are known Arf1-GEF proteins in S. cerevisiae.  
The Sec7 domain is present in all Arf-GEFs in both S. cerevisiae and mammals.  This 
domain is also the target of Brefeldin A, a fungal metabolite that can stabilize the 
abortive Arf1-GDP-Sec7 domain protein complex, thus preventing Arf1 from being 
activated through the Sec7 domain (Chardin & McCormick, 1999).  In mammals, Arf-
GEFs include the GBF1 family (mammalian orthologs of yeast Gea1 and Gea2), the BIG 
family (mammalian ortholog of yeast Sec7), the PSD family (mammalian ortholog of 
yeast Syt1), the IQSEC family (no yeast ortholog), the Cytohesin family (no yeast 
ortholog) and the FEXO8 family (no yeast ortholog) (Gillingham & Munro, 2007). 
Among SEC7, GEA1, GEA2, and SYT1, SYT1 is not essential and the syt1∆ strain 
was not identified in the global screening of gentamicin sensitivity (Blackburn & Avery, 
2003).  Thus, we further investigated gentamicin sensitivity in sec7, gea1, and gea2 
mutants.  As shown previously, while the wild-type strain was unaffected by gentamicin 
(Figure 7), a zuo1∆ strain was strongly inhibited. 
SEC7 is an essential gene of S. cerevisiae.  SEC7 encodes a 226kDa Arf-GEF 
protein which includes a 23kDa Sec7 domain.  Other than the Arf-GEF function, Sec7 is 
required for both mediating membrane tubule breakage and saccule fenestration at the 
cis-Golgi (Jackson, 2004) and the completion of ER-to-Golgi transport (Lupashin et al., 
1996).  For the latter, Sec7, with Ypt1, Sec19, Sly1, Uso1, and Sec18, are required for 
ER-derived transport vesicle to target the cis-Golgi membranes during the docking and 
tethering step which occurs before SNARE complex assembly and vesicle fusion 
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(Lupashin et al., 1996).  The idea that Sec7 can direct and scaffold the binding and 
disassembly of the COPI-COPII switch has also been proposed (Deitz et al., 2000). 
In our study, we utilized a strain containing the temperature-sensitive sec7-1 allele 
(gift from Dr. Peter Novick, Department of Cellular and Molecular Medicine, University 
of California, San Diego).  The sec7-1 allele has mutations that lie outside of the Sec7 
domain (Deitz et al., 2000) with a phenotype of blocked secretory pathway at the level of 
exit from the Golgi apparatus (Novick et al., 1980).  Our studies show that the growth of 
the sec7-1 strain is not affected by gentamicin (Figure 7).  This may suggest that the 
fission of tubules and fenestration of cisternal membranes are not significantly affected 
by gentamicin. 
Yeast Gea1 and Gea2 are 50% identical and functionally redundant (Peyroche 
et al., 2001).  Neither GEA1 nor GEA2 is an essential gene but the removal of both results 
in the loss of viability (Peyroche et al., 1996).  Here in our study, we utilized 
temperature-sensitive alleles of GEA1 (gifts from Dr. Jackson, Centre National de la 
Recherche Scientifique, France), gea1-4 gea1∆gea2∆ and gea1-6 gea1∆ gea2∆ strains, to 
determine whether gentamicin affects cells with reduced Gea1 activity (Peyroche et al., 
2001).  Genomic GEA1 and GEA2 were knocked out in both mutation strains but a 
temperature sensitive gea1 allele was integrated back into the genome in each strain 
(Table 1). 
Both Gea1 and Gea2 are located in the cis-Golgi compartment and can recruit 
COPI-coated vesicles (Jackson, 2004).  The gea1-6 gea1∆ gea2∆ and the gea1-4 gea1∆ 
gea2∆ mutants carry different mutations.  The gea1-4 allele carries multiple substitutions 
including two in the highly conserved Sec7 domain, while the gea1-6 allele only carries 
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two amino acid substitutions downstream of the Sec7 domain (Peyroche et al., 2001).  
Both ts mutants have defects in the generation of COPI-coated vesicles
 
from the Golgi 
and the gea1-6 gea1∆ gea2∆ mutant has a more severe phenotype with a dramatically 
slowed secretion of COPI-dependent proteins (Peyroche et al., 2001). 
At their permissive temperature (32ºC), the growth of the gea1
ts
 gea1∆gea2∆ 
strains in the presence or absence of gentamicin are shown in Figure 7.  Mid-log growth 
phase gea1-6 gea1∆gea2∆ mutant show growth inhibition at 500 µg/ml gentamicin.  
Mid-log growth phase gea1-4 gea1∆gea2∆ cells do not show detectable growth 
inhibition (Figure 7).  Among the different growth phases, the growth of late-log growth 
phase gea1-6 gea1∆gea2∆ cells is most affected by gentamicin (Figure 9); and gea1-4 
gea1∆ gea2∆ cells do not show detectable growth inhibition by gentamicin in any growth 
phase (Figure 9). 
In another study, it was proposed that even though Gea1 and Gea2 have 
overlapping functions, they are not redundant (Spang et al., 2001).  One of the reasons 
was that a gea1∆ arf1∆ mutant is sicker than an arf1∆ strain but still viable, whereas 
gea2∆ arf1∆ cells are inviable (Spang et al., 2001).  In the same paper, these investigators 
proposed that Sec7 could be the Arf-GEF solely responsible for
 
Golgi-to-vacuole 
anterograde trafficking and intra-Golgi retrograde trafficking, and Gea2 is mainly 
responsible for the early Golgi-to-ER retrograde
 
transport steps (Spang et al., 2001). 
Despite the different views of the function of each Arf-GEF, here, we show that 
cells with impaired Arf-GEF function, especially impaired Gea1 and Gea2 function, is 
hypersensitive to gentamicin. 
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4.2 The loss of Arf-GAP function and gentamicin hypersensitivity 
As mentioned previously, in S. cerevisiae, Gcs1, Glo3, Age1, and Age2 have been 
identified as Arf1-GAP proteins.  In mammals, Arf-GAPs include the Arf-GAP1 family 
(mammalian ortholog of yeast Gcs1), the Arf-GAP3 family (mammalian ortholog of 
yeast Glo3), the SMAP family (mammalian ortholog of yeast Age2), and seven other 
Arf-GAP families without a yeast ortholog (Gillingham & Munro, 2007). 
GCS1 was the first identified S. cerevisiae Arf-GAP encoding gene and Gcs1 has 
a cysteine-rich zinc finger, a so-called Arf-GAP domain (Cukierman et al., 1995; Poon 
et al, 1996).  GLO3, AGE1, and AGE2 were all identified later from a screening for high-
copy suppressors of the loss of ARF1 function mutants (Zhang et al, 1998).  Sequence 
homology searches identified the same Arf-GAP domain in Glo3, Age1, and Age2 and 
all of the four proteins have shown Arf-GAP activity in vitro (Poon et al., 1996, 1999, 
2001; Zhang et al., 2003).  SPS18 and GTS1 encode proteins that also contain the 
cysteine-rich Arf-GAP domain but have no detectable Arf-GAP activity in vitro (Zhang 
et al, 1998). 
The gcs1∆ mutants were found to be weakly sensitive to gentamicin (Blackburn 
& Avery, 2003).  A number of studies have suggested that Gcs1 has a more critical role 
than the other Arf-GAPs (Poon et al., 1996, 1999, 2001; Zhang et al., 2003).  Gcs1 
expressing cells are still viable despite a triple deletion of GLO3, AGE1 and AGE2 
(Zhang et al., 2003).  Gcs1 is activated only when vesicles are close to fission, thereby 
ensuring that the inactivation of Arf1 is delayed sufficiently to allow the generation of 
vesicles (Antonny, 2006). 
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In S. cerevisiae, although the deletion of AGE2 has no strong phenotype, cells 
lacking both AGE2 and GCS1 are inviable (Poon et al., 2001).  The same study also 
suggested that Gcs1 and Age2 form an essential Arf-GAP pair (Poon et al., 2001) that 
provides an overlapping function for vesicle transport from the trans-Golgi network to the 
vacuole and late endosomes (Poon et al., 2001). 
In a similar study from the same group, Gcs1 and Glo3 were proposed to form 
another Arf-GAP pair which provides an overlapping function for vesicle retrograde 
transport from the Golgi to the ER (Poon et al., 1999).  Even though single deletions of 
GCS1 or GLO3 are viable, deletion of both GLO3 and GCS1 is lethal, which indicates 
that Glo3 and Gcs1 may at least partially substitute for each other (Poon et al., 1999).  
The single deletion of GLO3 is viable but causes partial defects in Golgi-to-ER traffic 
(Poon et al., 1999). 
We tested gentamicin sensitivity on the gcs1
ts gcs1∆ age2∆ mutant strain 
(PPY 164-5D, Table 1) and the gcs1
ts gcs1∆ glo3∆ mutant strain (PPY 147-28-2A, 
Table 1; both strains were kind gifts from Dr. Poon, Department of Biochemistry and 
Molecular Biology, Dalhousie University, Nova Scotia, Canada) at their permissive 
temperature (room temperature) (Figure 8).  As we predicted, wild-type cells (BY4741, 
Table 1) are not affected by gentamicin.  On plates with different concentrations of 
gentamicin, the zuo1∆ strain shows growth inhibition.  The gcs1-3 gcs1∆ age2∆ strain 
was not affected by gentamicin at a concentration of up to 500 µg/ml.  The gcs1-28 
gcs1∆ glo3∆ strain shows clear growth inhibition at a gentamicin concentration of 250 
µg/ml. 
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We also examineded the gentamicin sensitivity of gcs1
ts
 cells from different 
growth phases (Figure 9).  The growth of gcs1-28 gcs1∆ glo3∆ cells from all growth 
phases (early-, mid-, and late-log growth phase) is affected by gentamicin (Figure 9); 
while gcs1-3 gcs1∆ age2∆ cells do not show detectable growth inhibition by gentamicin 
in any growth phase (Figure 9). 
Age1 and Age2 are not functionally redundant since the double deletion of AGE2 
and GCS1 is lethal (Poon et al., 2001) and growth of a strain with a double deletion of 
both AGE1 and AGE2 is indistinguishable from wild-type strains (Zhang et al., 2003).  At 
this point, we only know that neither the age1∆ nor age2∆ strains were identified from 
the global screening for gentamicin sensitive strains (Blackburn & Avery, 2003). 
This data supports the model that impaired Gcs1/Glo3 protein pair function leads 
to gentamicin hypersensitivity.  Interestingly, this Arf-GAP pair has a partial block of 
vesicle retrograde transport from the Golgi to the ER. 
5   Cellular CPY Processing in the Absence or Presence of Gentamicin 
5.1 CPY processing in wild-type cells unaffected by gentamicin 
Carboxypeptidase Y (CPY) is a soluble vacuolar hydrolase enzyme that removes 
amino acids from the carboxyl terminus of a protein or a peptide (Chiang & Schekman, 
1991).  On its way to the vacuole, CPY goes through several stages of post-translational 
modification and is sorted through the secretory pathway (Stevens et al., 1982).  Since the 
1980s, CPY has been a widely used reporter for monitoring the movement of proteins 
through the secretory pathway (Valls et al., 1987). 
The processing pathway of CPY has been very well characterized (Losev et al., 
2006; Valls, Hunter et al., 1987).  CPY is synthesized as an inactive precursor protein and 
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translocated into the ER-lumen as a result of its 20-amino acid signal peptide.  The signal 
peptide is then proteolytically removed and CPY undergoes dolichol-mediated core 
glycosylation in the ER-lumen.  The addition of core oligosaccharides produces a 67 kDa 
premature ER form of CPY (pl form).  During the transit of the p1 form of CPY through 
the Golgi complex, three of the four core oligosaccharides on CPY are elongated to 
produce carbohydrate side chains containing an average of 11 to 18 mannoses.  The fully 
glycosylated premature Golgi form (p2 form) has a molecular mass of 69 kDa.  Then 
CPY binds to its receptor, Vps10,
 
and is sorted into vesicles at the late Golgi that are 
targeted to fuse
 
with the prevacuolar/endosomal compartment.  Upon arrival in the 
vacuole, the N-terminal propeptide segment of CPY is proteolytically removed to 
generate an active 61 kDa mature CPY (mature form).  The recycling of CPY receptor, 
Vps10, is regulated by the retrograde trafficking pathway (Marcusson et al., 1994). The 
half-time for the maturation process has been shown to be approximately 6 minutes 
(Losev et al., 2006). 
We examined whether cells with mutant forms of Arf1, Arf-GEFs, or Arf-GAPs 
have defects in CPY processing in the presence of gentamicin (Figure 10).  Firstly, no 
premature CPY accumulation in the wild-type strain (BY47141) was seen, even after 
inoculation in gentamicin for up to 8 hours (Figure 10). 
5.2 Disruption of cellular CPY processing in Arf1 or Arf1 regulator mutants by 
gentamicin 
We do not observe premature CPY accumulation in the arf1∆ strain when cells 
were inoculated in YPD media (Figure 10), but, premature CPY accumulation of both p1 
(ER) and p2 (Golgi) forms were observed in these cells after 4 hours of incubation in 
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YPD + gentamicin (500 µg/ml).  After a longer incubation (8 hours) with gentamicin, an 
increased accumulation of both p1 (ER) and p2 (Golgi) premature forms of CPY was 
observed.  For the arf2∆ strain, we do not observe premature CPY accumulation, even 
with up to 8 hours of incubation in gentamicin (500 µg/ml).  This result is consistent with 
the literature that ARF1 can complement the loss of ARF2 but ARF2 cannot complement 
the loss of ARF1 since the arf2∆ strain displays no growth phenotype, but the arf1∆ cells 
grow slowly and are cold sensitive (Stearns, et al., 1990). 
For the strains that lacked both ARF1 and ARF2 but were kept alive by the 
presence of a temperature sensitive allele of ARF1 (arf1-11, arf1-16 or arf1-18, Table 1), 
we observed different premature CPY accumulation patterns before and during 
gentamicin incubation.  We noticed very poor growth of both arf1-11 arf1∆ arf2∆ cells 
and arf1-16 arf1∆ arf2∆ cells after the addition of gentamicin.  The arf1-11 arf1∆ arf2∆ 
strain had a very small amount of the p1 (ER) form of premature CPY already present 
before incubation with gentamicin.  The accumulation of both p1 (ER) and an equal 
amount of p2 (Golgi) forms of premature CPY are observed after the addition of 
gentamicin (to a final concentration of 500 µg/ml).  The arf1-16 arf1∆ arf2∆ strain had a 
similar amount of the p1 (ER) form of premature CPY before and during incubation in 
gentamicin (to a final concentration of 500 µg/ml).  This phenomenon can be explained if 
the cells stopped growing soon after the addition of gentamicin.  The arf1-18 arf1∆ arf2∆ 
strain did not have premature CPY accumulation when cells were incubated in YPD 
media.  After 8 hours of incubation in gentamicin, premature CPY accumulation was 
observed for both p1 (ER) and p2 (Golgi) forms (Figure 10).  These results also indicate 
that the arf1-11 arf1∆ arf2∆ and arf1-16 arf1∆ arf2∆ strains had ER to Golgi trafficking 
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blocked, even when cells were cultured in YPD medium.  When gentamicin (500 µg/ml) 
was added to the YPD media, arf1-11 arf1∆ arf2∆ cells showed blocks to both ER to 
Golgi trafficking and inter/post-Golgi trafficking.  The arf1-18 arf1∆ arf2∆ cells did not 
show blockage in intracellular trafficking when cultured in YPD medium, but cells 
showed blocks to both ER to Golgi trafficking and inter/post-Golgi trafficking after 
incubation in gentamicin (500 µg/ml) for 8 hours (Figure 10). 
We also examined CPY processing in the Arf-GEF mutant strains.  While in the 
single Arf-GEF deletion strains SEC7/sec7∆ (heterozygous) and syt1∆, CPY processing 
was not blocked before or after incubation in gentamicin (to a final concentration of 500 
µg/ml) (Figure 10), the gea1∆ strain accumulated premature CPY of both p1 (ER) and p2 
(Golgi) forms but only after incubation in gentamicin (500 µg/ml).  The result with the 
gea1∆ strain was also consistent with the gea1-4 gea2∆ and gea1-6 gea2∆ strains.  Like 
the SEC7/sec7∆ strain, the sec7-1 strain did not show premature CPY accumulation, even 
with up to 8 hours of incubation in gentamicin (500 µg/ml) (Figure 10). 
We then examined the CPY processing in the Arf-GAP mutant strains.  While the 
gcs1∆ strain showed a similar amount of premature CPY accumulation in only the p1 
(ER) form (before and after incubation in gentamicin), glo3∆ cells showed an increasing 
amount of premature CPY also in the p1 (ER) form only but after incubation in 
gentamicin (Figure 10).  The age2∆ strain had premature CPY accumulation of both p1 
(ER) and p2 (Golgi) forms only after incubation in gentamicin (500 µg/ml) (Figure 10).  
The CPY processing phenotype of gcs1-28 gcs1∆ glo3∆ cells was very similar to gcs1∆ 
cells and glo3∆ cells, and the CPY processing phenotype of gcs1-3 gcs1∆ age2∆ cells 
was very similar to age2∆ cells (Figure 10).  These results indicated that the gcs1∆, 
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glo3∆ and gcs1-28 gcs1∆ glo3∆ strains had ER to Golgi trafficking blocked before and 
during incubation in gentamicin (500 µg/ml).  The age2∆ and gcs1-28 gcs1∆ age2∆ 
strains had blocks to both ER to Golgi trafficking and inter/post-Golgi trafficking when 
incubated with gentamicin (500 µg/ml) (Figure 10).  Since Gcs1 and Glo3 work together 
as an Arf-GAP pair to provide an overlapping function for vesicle retrograde transport 
from the Golgi to the ER, and Gcs1 and Age2 work together as another Arf-GAP pair to 
regulate late Golgi-vacuole transport (Poon et al., 2001), the loss of GLO3 or AGE2 
prevents specific trafficking steps which are regulated by these Arf-GAP pairs. 
Arf1 is required for the budding of COPI-coated vesicles which requires 
coatomer, a stable cytosolic complex comprising seven equimolar subunits, α-, β-, β′-, γ-, 
δ-, ε-, and δ-COP (Michelsen et al., 2007).  Binding of Arf1-GTP to Golgi membranes 
leads to recruitment of the coatomer, deformation of the membrane, and budding of 
COPI-coated vesicles.  COPI-coated vesicles mediate an essential and conserved retrieval 
pathway that continually recycles several classes of proteins, and lipids, from the cis-
Golgi back to the ER (Eugster et al., 2004).  It has been reported that the WD40 domains 
of the α-and β′-COPI subunits can recognize C-terminal di-lysine motifs (K(X)KXX) 
(where K is lysine and X is any amino acid) on ER membrane proteins (Eugster et al., 
2004), and two highly conserved stretches in the β-and δ-COPI subunits can recognize 
Arginine (R)-based ER localization signals (Michelsen et al., 2007).  When the ARF1 
pathway is inhibited by gentamicin, COPI mediated retrograde trafficking is partially 
blocked.  Thus, ER lumenal and ER membrane proteins fail to be retrieved from the 
Golgi back to the ER, which in return affects anterograde trafficking from the ER to the 
Golgi. 
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Thus, in some of the strains we tested which have defects in ARF1 pathway 
components, CPY trafficking and processing are further blocked by gentamicin (500 
µg/ml) (Figure 17). 
6   Enrichment of Arf1-TAP Protein by Gentamicin-binding Resin 
One possible explanation for the effects of gentamicin on the ARF1 pathway is 
that gentamicin can directly bind to Arf1 or Arf1 effectors, thus affecting Arf1 activity 
in vivo.  This hypothesis was inspired by the binding of Brefeldin A (BFA) to the Arf1-
GDP-Sec7 complex (Chardin & McCormick, 1999).  In order to test this hypothesis, 
yeast whole cell extract was incubated with gentamicin-bound resin or empty (negative 
control) resin. 
Both resins were prepared as described in Materials and Methods.  Briefly, after 
being incubated with the same yeast ARF1-TAP strain (Table 1) whole cell extract, both 
resins were washed four times with lysis buffer before a final elution with elution buffer 
(lysis buffer + 10 mM gentamicin). 
The concept of gentamicin affinity-binding pull-down assays has been used in 
similar studies to identify the gentamicin binding proteins disulfide isomerase (Horibe 
et al., 2001), heat shock protein 90 kDa beta member (Horibe et al., 2004), calreticulin 
(Horibe et al., 2004) and heat shock 70 kDa protein (Miyazaki et al., 2004) in mammals.  
In this study, we modified the assay and applied yeast whole cell extract to the resin.  We 
detected no protein bound to the empty (negative control) resin (details are included in 
Results: Chapter 3). 
In our experiments, in different batches, GDP (to a final concentration of 10 mM) 
or GTPγS (to a final concentration of 10 mM) was premixed with yeast whole cell extract 
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before the incubation with resin.  When GDP was added in vitro, the GDP concentration 
in the yeast whole cell extract was much higher (> 10
5
 fold) than GTP, and the majority 
of Arf1 in the whole cell extract was in the GDP-bound form.  With the in vitro addition 
of GTPγS (> 105 fold more concentrated than GDP in the whole cell extract), which is a 
nonhydrolyzable analog of GTP, the majority of Arf1 is in the GTP-bound form. 
As shown in Figure 11, after three consecutive washes, no more non-specific 
bound Arf1-TAP protein was detected on the resins (Figure11A and 11B).  And no Arf1-
TAP protein was eluted from the empty (negative control) resin (Figure 11B).  But Arf1-
TAP was eluted from the gentamicin-bound resin by 10 mM gentamicin in the elution 
buffer (Figure 11A).  The addition of GDP (10 mM) or GTPγS (10 mM) did not change 
the Arf1-TAP binding ability to the gentamicin-bound resin (Figure 11C and 11D). 
We have attempted to use several yeast Arf1 antibodies unsuccessfully (Millipore, 
Anti-ARF1 monoclonal antibody, Cat # MAB3779; Chemicon, Anti-ARF1 monoclonal 
antibody, Lot # 25040787; Epitoics, ARF1 rabbit monoclonal antibody, Cat # 1635-1).  
We finally decided to test the binding ability of rat Arf1 to our gentamicin-bound resin 
and to detect possible rat Arf1 binding by our customized rabbit anti-ratArf1 antibody.  
Figure 11E shows convincingly that our rabbit anti-rat Arf1 antibody readily detects rat 
Arf1 (21KDa) while the rabbit pre-immune serum does not recognize rat Arf1 protein.  
We also noticed that after the incubation of rat cytosol with gentamicin-bound resin, there 
was no non-specific bound rat Arf1 protein remaining on the resin after the first of four 
consecutive washes (Figure 11F).  But consistent with our previous yeast Arf1-TAP 
strain assay, rat Arf1 was eluted from the gentamicin-bound resin by elution buffer with 
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10 mM gentamicin.  This result suggests that rat Arf1 is also capable of binding and is 
enriched by gentamicin-bound resin. 
In brief, our results show that a gentamicin-bound resin can enrich for Arf1 
in vitro.  Furthermore, Arf1 binding to gentamicin-bound resin can be enhanced in a 
GTP/GDP-dependent manner.  But from this experiment, we cannot tell whether Arf1 
can bind to gentamicin directly or indirectly since the binding could be through an Arf1 
effector from an Arf1 complex. 
We have successfully expressed and purified N-terminal His-tagged yeast Arf1 
protein (plasmid pLH-YARF1, Table 2) in E. coli, but the instrument iTC200
®
 (MicroCal, 
Piscataway, NJ) that we used to measure the direct binding of small molecules 
(gentamicin) to protein (N-terminal His-tagged yeast Arf1 protein) has not allowed us to 
detect a direct gentamicin-Arf1 interaction as of yet.  We as yet do not know whether 
Arf1 protein can directly bind to gentamicin. 
When the purified proteins (Arf1 or Sse1) were concentrated by VivaSpin
 
500, 
MWCO 3kDa (GE healthcare, NJ), the binding Kd of gentamicin to Sse1 or Arf1 was 23 
µM and 77 µM, respectively.  (For the measuring of Arf1 binding ability, 
[Arf1]=0.18mM and [gentamicin]=3.5mM; for the measuring of Sse1 binding ability, 
[Sse1]=0.055mM and [gentamicin]=1mM.)  But since I noticed insoluble debris on the 
bottom of the VivaSpin tubes, I switched to VivaSpin 500, MWCO 10kDa (GE 
healthcare, NJ).  No cell debris was observed any more, but I lost both binding titration 
curves as well.  From Coomassie blue stained acrylamide gels, I did not see any 
difference by using Visaspin 500, MWCO 3kDa or Visaspin 500, MWCO 10kDa. 
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7   Gentamicin Sensitivity of S. cerevisiae Strains with only hArf4 or bArf1 as the 
Functional Arf 
Arf protein function is conserved among eukaryotic organisms.  In mammalian 
cells, there are six ARF proteins that have been identified.  Even though mARF1 and 
yARF1 are only about 74% identical, each of the six mammalian ARFs can complement 
the deletion of both yARF1 and yARF2 (reviewed in Donaldson & Jackson, 2000).  The 
six mammalian Arf proteins fall into three classes by sequence comparison (Kahn et al., 
1991; Moss & Vaughan, 1995).  Class I ARFs (Arf1-Arf3) are the best studied and 
appear to be functionally redundant.  Class I ARFs control the formation of different 
vesicle coats in intracellular membrane transport.  The function of class II ARFs (Arf4 
and Arf5) is unclear.  The only member of class III is Arf6 which is found on the plasma 
membrane and has been suggested to regulate membrane trafficking and cytoskeleton 
organization (Gillingham & Munro, 2007; Pucadyil & Schmid, 2009). 
Studies showed that the expression of any human Arf, which includes hArf1, 
hArf2, hArf3, hArf4, hArf5, and hArf6, is able to rescue the lethality of  yeast 
S. cerevisiae arf1∆ arf2∆ double mutants, which we studied in this experiment (Kahn 
et al., 1991). 
Bovine Arf1 (100% identical to hArf1 in amino acid sequence) is a member of the 
class I ARFs and the hArf4 is a member of the class II ARFs (Gillingham & Munro, 
2007; Pucadyil & Schmid, 2009).  Strain 121.13C and strain RT166 (Table 1) were both 
kind gifts from Dr. Kahn (Kahn et al., 1991).  In brief, in the strain 121.13C, bARF1 is 
expressed under a GAL1 promoter from plasmid pJCB1-21, to make the yeast arf1∆ 
arf2∆ double deletion strain viable.  In the strain RT166, hARF4 is expressed under the 
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same GAL1 promoter from plasmid pJCH2-8, to make the yeast arf1∆ arf2∆ double 
deletion strain viable.  Importantly, it has been shown that the level of hARF4 expressed 
under the control of the GAL1 promoter in the absence of any yeast ARF‟s is 
indistinguishable from that of yARF1 expressed from its own promoter (Kahn et al., 
1991).  The level of bARF1 expressed under the control of the same GAL1 promoter in 
the absence of any yeast ARFs is 3-10 fold higher, but bARF1 product has a lower 
“specific activity” in yeast (Kahn et al., 1991). 
We examined gentamicin sensitivity of the hArf4-expressing strain and the bArf1-
expressing strain on YPGal plates in the presence or absence of gentamicin (Figure 12).  
The WT strain (BY4741), hArf4-expressing strain, and bArf1-expressing strains grow 
equally well on YPGal plates without gentamicin.  However, while the growth of the WT 
strain is not affected by gentamicin (up to 500 µg/ml), bArf1-expressing strains are 
sensitive to gentamicin at concentrations of 250 µg/ml (and at even lower concentration 
as observed from liquid culture results).  There was no significant sensitivity difference 
between cells from different growth phases. 
From the phylogenetic analysis of the Arf cDNA sequences, yArf1 is more 
closely related to hArf1 (100% identical to bArf1 in amino acid sequence) than to hArf4 
(Tsuchiy et al., 1991).  And from amino acid sequence analysis, yArf1 is 77% identical to 
hArf1 and 72% identical to hArf4p, which are only slightly less than the identity between 
hArf1 and hArf4 (80%) (Welsh et al., 1994).  Our results here show that Class I Arfs can 
be more sensitive to gentamicin than Class II Arfs. 
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8   Summary of the ARF1 pathway in Response to Gentamicin 
A genetic screening by Blackburn and Avery revealed that at least 20 genes are 
required for gentamicin resistance in S. cerevisiae (Blackburn & Avery, 2003).  Based on 
the genetic interactions between hypersensitive mutants and their products, we propose 
that the ARF1 pathway itself is a target of and is affected by gentamicin (Figure 3). 
Firstly, since Arf1 and Arf2 are functionally interchangeable (Stearns et al., 1990) 
and we observed no gentamicin hypersensitivity in single deletion strains of either arf1∆ 
or arf2∆, we applied spot dilution assays of ARF1 arf2∆ and arf1ts arf1∆ arf2∆ stains.  
The result showed that all of the arf1
ts
 arf1∆ arf2∆ cells are hypersensitive to gentamicin 
(Figure 4) which indicates that the loss of Arf1 function can cause yeast cells to become 
hypersensitive to gentamicin. 
Secondly, we noticed that while the total Arf1 expression level remained constant, 
regardless of the absence or presence of gentamicin (500 μg/ml) in the media or the 
different growth phases of the cells (Figure 5B), GTP-bound Arf1 varied with gentamicin 
(500 μg/ml) in the media in the different growth phases (Figure 5A and 5C).  This result 
shows that gentamicin can affect the level of GTP-bound Arf1 in a cell growth phase-
dependent manner, even though total Arf1 expression level in S. cerevisiae is not affected 
by gentamicin (500 μg/ml). 
Thirdly, we showed that cells with impaired Arf-GEF or Arf-GAP functions are 
hypersensitive to gentamicin (Figure 7, Figure 8 and Figure 9).  In particular, cells with 
mutations in the Gea1/2 proteins or the Gcs1/Glo3 protein pair are more sensitive to 
gentamicin (Figure 7, Figure 8 and Figure 9). 
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Fourthly, we examined whether cells with mutations in ARF1, ARFGEF genes, or 
ARFGAP genes had defects in intracellular traffic and CPY processing in the presence of 
gentamicin (Figure 10).  We do not observe premature CPY accumulation in the wild-
type strain (BY47141) after incubation in gentamicin for up to 8 hours, but in arf1∆, 
arf1-11 arf1∆ arf2∆, arf1-18 arf1∆ arf2∆, gea1∆, gea1-6 gea2∆, glo3∆ and age2∆ 
strains, CPY trafficking and processing are further blocked by gentamicin (500 µg/ml) 
(Figure 10). 
Fifthly, we showed that a gentamicin-bound resin can enrich both yeast Arf1-TAP 
protein and rat Arf1 protein in vitro (Figure 11).  In yeast, Arf1 binding to gentamicin-
bound resin is enhanced in a GTP/GDP-dependent manner (Figure 11C and 11D).  But at 
present, we cannot tell whether Arf1 is binding to gentamicin directly. 
Finally, we showed that in S. cerevisiae double deletion strains that lack both 
ARF1 and ARF2 but are kept alive by the presence hArf4 or bArf1 (100% identical to 
hArf1 in amino acid sequence), are hypersensitive to gentamicin (Figure 12).  This result 
supports the idea that mammalian Arfs are more vulnerable to gentamicin and can at least 
partially explain the increased sensitivity of mammalian cells to gentamicin. 
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CHAPTER 2: INCREASE OF -1 PROGRAMMED RIBOSOMAL 
FRAMESHIFTING EFFICIENCY BY GENTAMICIN 
1   Confirmation of the Dual-reporter Plasmid Sequence 
Dr. Dinman (University of Maryland) has kindly provided us plasmids pYDL-
control, pYDL-LA, and pYDL-TY1 (Table 2), for in vivo dual-luciferase assays (Harger 
& Dinman, 2003).  Plasmids were amplified in the E. coli DH5α strain and confirmed by 
automated dye-terminator sequencing. 
The sequencing results proved that the programmed ribosomal frameshifting 
signals utilized in the constructs were from yeast L-A virus (for the -1 Programmed 
Ribosomal Frameshifting signal, -1 PRF) (Fujimura et al., 1992) and Ty1 virus (for the 
+1 Programmed Ribosomal Frameshifting signal, +1 PRF) (Mellor et al., 1985).  Plasmid 
sequencing results of dual-luciferase reporter genes are shown in Figure 2.  The -1 PRF 
signal includes a special sequence, X XXY YYZ (the 0-frame is indicated by spaces), 
which is called a “slippery site”.  Also, a downstream secondary structure which usually 
forms an mRNA pseudoknot (as in pYDL-LA) is located immediately 3‟ to the slippery 
site.  The pseudoknot can transiently cause the ribosome to pause during translation and 
the pause is required for the promotion of efficient -1 PRF (Figure 2B).  Ty1 +1 PRF 
occurs when a peptidyl-tRNAUAG (Leu) slips +1 between CUU and UUA leucine codons 
(Figure 2C).  This +1 PRF slippage occurs during a translational pause induced by slow 
recognition and low availability of the next in-frame peptidyl-tRNAAGG coding for 
arginine (Boeke et al., 1998). 
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2   Effect of Gentamicin on -1 Programmed Ribosomal Frameshifting  
Yeast S. cerevisiae BY4741 strains harboring either pYDL-control (LL231) or 
pYDL-LA (LL232) were used in this experiment (Table 2).  Cells were cultured in YPD 
or YPD + gentamicin (to a final concentration of 500 µg/ml) as indicated.  Cells were 
harvested at mid-log growth phase.  Raw data readings were collected with a Monolight
®
 
2010 Luminometer (Analytical Luminescence Laboratory). 
Encoded from the plasmid pYDL-control, the Renilla luciferase and Firefly 
luciferase are in the same reading frame and will always be translated into a fusion 
protein that has both Renilla luciferase and Firefly luciferase activity (Table 3 and Table 
4).  In contrast, encoded from the pYDL-LA, the Renilla luciferase and Firefly luciferase 
are not in the same reading frame.  Without -1 PRF, the ribosome will meet a stop codon 
before reaching the coding sequence of Firefly luciferase.  Thus, no functional Firefly 
luciferase will be expressed.  In the case of a -1 PRF occurrence, Renilla luciferase and 
Firefly luciferase will be in the same reading frame again and will be translated into a 
fusion protein that has both Renilla luciferase and Firefly luciferase activity (Table 3 and 
Table 4). 
The important measurement in this experiment is the ratio of Firefly luciferase to 
Renilla luciferase expression encoded from the L-A plasmid versus the same ratio 
encoded from the control plasmid, which represents the frequency of -1 PRF.  Both ratios 
need to be normalized before further comparison (Table 5). 
The experiments were carried out with a relatively large sample size (Table 3 and 
Table 4) to meet requirements for statistical analysis.  In YPD, 14 replicates of the LL231 
strain were tested (including one outlier that is not shown) and 31 replicates of the LL232 
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strain were tested (including three outliers that are not shown).  In YPD + gentamicin 
(500 µg/ml) medium, 23 replicates of the LL231 strain were tested (including three 
outliers that are not shown) and 33 replicates of the LL232 strain were tested (including 
one outlier that is not shown). 
The raw data were processed with Dr. Dinman‟s online version of the modified 
protocol “Systematic analysis of bicistronic reporter assay data” (Jacobs & Dinman, 
2004).  After the outliers were excluded from the raw data set, each set of data was tested 
and shown to be linear and normally distributed.  The actual sample sizes were all above 
the “corrected sample size” (Kupper & Hafner, 1989).  The statistical result showed that  
-1 PRF efficiency in the absence of gentamicin is 2.3 ± 0.1% (Table 5); while with 500 
µg/ml gentamicin, the -1 PRF efficiency increases to 7.1 ± 0.2%, which is a 3-fold 
increase (Table 5).  The -1 PRF efficiency of the no gentamicin set and the plus 
gentamicin set were statistically different, since the p-value was much less than 0.01 
(8.17E-26), which corresponded to much less than a 1% chance of there being no 
statistical difference between the two sets. 
3   Effect of Gentamicin on +1 Programmed Ribosomal Frameshifting  
The S. cerevisiae BY4741 strains harboring either the pYDL-control (LL231) or 
the pYDL-TY1 (LL233) were used in this experiment (Table 2).  Cells were cultured in 
YPD or YPD + gentamicin (to a final concentration of 500 µg/ml) as indicated.  Cells 
were harvested in the mid-log growth phase. 
The experimental design was the same as with the -1 PRF. The only difference 
was that the +1 PRF signal was inserted between the Firefly luciferase and the Renilla 
luciferase instead of the -1 PRF signal. 
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The experiments were also carried out with a relatively large sample size (Table 3 
and Table 4).  In YPD medium, 14 replicates of the LL233 strain were tested (including 
two outliers that are not shown).  In YPD + gentamicin (500 µg/ml) medium, 26 
replicates of the LL233 strain were tested (including one outlier that is not shown). 
The raw data were processed in the same manner as the -1 PRF data.  The 
statistical result shows that the +1 PRF efficiency in the absence of gentamicin is 11.0 ± 
0.2% (Table 5); while with 500 µg/ml gentamicin, the +1 PRF efficiency decreases to 9.1 
± 0.2%, which is a 17% decrease (Table 5).  The +1 PRF efficiencies of the no 
gentamicin set and the plus gentamicin set are statistically different, since the p-value is 
much less than 0.01 (2.01E-22), which corresponds to much less than a 1% chance of 
having no statistical difference between the two sets. 
4   Documented Programmed Ribosomal Frameshifting of Yeast S. cerevisiae 
Programmed ribosomal frameshifting was originally discovered in viruses and 
prokaryotes.  But now, a growing number of examples have proved the existence of PRF 
signals in expressed eukaryotic genes (Lundblad & Morris, 1997; Morris & Geballe, 
2000; Wills, Moore et al., 2006).  In a pioneering study by Dr. Dinman‟s group, based on 
a computational sequence analysis, it was suggested that among the 6,353 Open Reading 
Frames (ORFs) of the yeast S. cerevisiae, 1,275 ORFs contained at least one strong -1 
PRF signal (Jacobs et al., 2007).  To prove the computational analysis, they tested 
selected candidates in vivo in the same study.  The results indicated that eight out of nine 
-1 PRF signals tested promoted efficient -1 PRF in vivo. 
The efficiency of programmed ribosomal frameshifting is affected by the host 
strain (either Wild-type or mutant strain) and the PRF signal that is being studied (Carr-
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Schmid et al., 1999; Muldoon-Jacobs & Dinman, 2006).  When using a wild-type 
S. cerevisiae strain as a host, in the study of L-A -1 PRF signals or Ty1 +1 PRF signals, 
4% to 10% PRF efficiencies have been observed (Muldoon-Jacobs & Dinman, 2006; 
Jacobs et al., 2007). 
Studies have also tested the PRF efficiency in mutant yeast strains, such as the 
ssz1 zuo1 double deletion strain and the ssb1 ssb2 double deletion strain (Muldoon-
Jacobs & Dinman, 2006).  The results showed the deletion of ssz1 zuo1 or ssb1 ssb2 
inhibited -1 PRF but had no detectable effect on +1 PRF.  The explanation for the 
inhibition of the -1 PRF was that impaired chaperone function causes nascent peptides to 
aggregate and blocks the polypeptide exit tunnel, and thus the movement of newly 
synthesized peptides into the tunnel.  As a consequence, the peptidyl-tRNA 3‟ end is mis-
positioned and both translation and frameshifting are partially inhibited (Muldoon-Jacobs 
& Dinman, 2006). 
5   Consequences of Programmed Ribosomal Frameshifting Efficiency Changes 
Notably, studies have pointed out that nearly all PRF events would directly lead 
translation elongation into premature termination, thus generating the hypothesis that 
PRF can be used to target mRNA for degradation via the nonsense-mediated mRNA 
decay pathway (NMD).  In addition, cells could use trans-acting factors of PRF to post-
transcriptionally regulate gene expression (Muldoon-Jacobs & Dinman, 2006).  
Considering the ORFs in the yeast S. cerevisiae that contain certain +1 PRF or -1 PRF 
signals, different PRF efficiencies may affect gene expression on a large scale. 
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CHAPTER 3: MASS SPECTROMETRY ANALYSIS OF GENTAMICIN 
BINDING PROTEINS 
1   Comparison of Gentamicin-binding Proteins with Existing Data 
From the eight gentamicin-bound resin elution injections (duplicate injections for 
each biological replicate), 67 proteins were reproducibly identified by LC-MS/MS (Table 
6).  These IDs were considered reproducible since proteins were identified by LC-
MS/MS more than once. The identification of a protein is based upon the PeptideProphet 
and ProteinProphet algorithms.  A protein was considered identified if the protein had 
1) a protein probability value > 0.9; and 2) two or more unique peptides with each 
individual peptide probability value > 0.9.  Proteins with only one unique peptide were 
excluded due to their higher false discovery rate. 
Trypsin was the only protein that was identified from the eight empty (negative-
control) resin elution injections (duplicate injections for each biological replicate).  For 
mass spectrometry analysis, trypsin (porcine) is added to digest proteins into smaller 
peptides (Domon & Aebersold, 2006). 
Previous studies have identified several gentamicin-binding proteins in mammals, 
including protein disulfide isomerase (PDI, UniProtKB: P05307) (Horibe et al., 2001), 
heat shock protein 90 kDa beta member (GRP94, UniProtKB: Q95M18) (Horibe et al., 
2004), calreticulin (CRT, UniProtKB: P52193) (Horibe et al., 2004) and heat shock 
70 kDa protein (HSP73, UniProtKB: CAN13333 and CAN87708) (Miyazaki et al., 2004). 
In our study, many S. cerevisiae proteins with mammalian homologs were 
identified, such as Pdi1 (29% identity with PDI in amino acid sequence), Hsc82 and 
Hsp82 (46% identity with GRP94 in amino acid sequence) and Ssa1, Ssa2, Kar2, Ssb1, 
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Ssb2 and Sse1 (72%, 72%, 60%, 59%, 58% and 34% identity with Hsp73 in amino acid 
sequence, respectively), were all identified in our gentamicin-binding protein list (Table 6, 
column 5).  Yeast protein Cne1 (the only yeast homologous of CRT, 30% identity in 
amino acid sequence) was not identified (Horibe et al., 2004), probably because in 
S. cerevisiae, Cne1 does not have Ca
2+ 
binding ability (Xu et al., 2004). 
2   Evaluation of the Gentamicin-binding Protein Dataset 
Gentamicin-binding proteins were plotted against their protein expression levels 
(Figure 13A).  Interestingly, the previously identified gentamicin-binding proteins all 
have relatively high expression levels (1E+05 to 1E+06 molecules/cell) (Horibe et al., 
2004; Miyazaki et al., 2004).  In our gentamicin-binding protein dataset, the protein 
expression levels distribute across a wider range, from 1E+03 molecules/cell to 1E+06 
molecules/cell.  Among the 55 proteins with expression data, 28 proteins were detected in 
more than three injections and the rest were detected in three or fewer injections.  We 
noticed that some low-abundance proteins were detected more often than high-abundance 
proteins, which indicates protein detection is not only based on protein abundance. 
Since smaller proteins with a relative molecular mass (Mr) of less than 35,000 Da 
are less likely to be identified by mass spectrometry (Krogan et al., 2006) (mainly 
because they have less peptides than bigger proteins), gentamicin-binding proteins were 
plotted against their molecular mass (Figure 13B).  In our protein dataset, 43 proteins 
(over half of the proteins) were successfully identified by LC-MS/MS despite their low 
molecular masses (Mr < 35,000). 
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3   Identification of Functional Protein Complexes and Protein Networks  
Proteins on our gentamicin-binding protein list could either directly or indirectly 
bind to the gentamicin molecule.  To distinguish the gentamicin-binding proteins from 
their binding partners, we took advantage of a recently reported CYC2008 protein 
complex dataset (http://wodaklab.org/cyc2008/) (Pu et al., 2009).  CYC2008 included 
408 manually curated yeast complexes derived from small-scale studies in the current 
literature.  Even though more protein complexes have been identified by large-scale high-
throughput studies, this database fit our focus by organizing protein complexes according 
to their biological functions. 
Based on the CYC2008 database, 33 gentamicin-binding proteins were grouped 
into four protein complexes: the eukaryotic elongation factor-1 (eEF-1) complex (Figure 
14A), the ribosome-associated chaperone (RAC) complex (Figure 14C), the cytoplasmic 
ribosomal large subunit (Table 7) and the cytoplasmic ribosomal small subunit (Table 7).  
It is not surprising to discover that gentamicin has a strong interaction with ribosomal 
large and small subunits, maybe through rRNA.  However, eEF-1 and RAC have never 
been reported to interact with gentamicin previously. 
The Osprey software program (http://en.bio-soft.net/protein/Osprey.html) 
(Breitkreutz et al., 2003) was used to design an interaction network between eEF-1 and 
the remaining proteins that are on the gentamicin-binding protein list but had not been 
grouped into complexes yet (Figure 14A).  The network revealed eight proteins, Yef3, 
Hyp2, Pab1, Sbp1, Mam33, Cmd1, Tpm1 and Ede1, that can be eEF-1 binding partners.  
In a systematic study of identification of protein complexes in S. cerevisiae, Abp1 and 
YKL056C encoding protein were found associated with Hyp2 and Ede1 in the same 
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protein complex (Costanzo et al., 2010).  Bbc1 is in another protein complex with Hyp2 
(Gruhler et al., 2002). 
Both on the gentamicin-binding protein list, Hsc82 and Hsp82 are homologous to 
GRP94, which has shown binding ability with gentamicin in mammals in a previous 
study (Horibe et al., 2004).  A protein-protein interaction network of Hsc82, Hsp82 and 
the remaining ungrouped proteins was developed (Figure 14B).  Nine more proteins 
(Bmh1, Def1, Sba1, Vma4, Hsp60, Hcr1, Lat1, Sgt2 and Cdc37) were grouped as Hsc82 
and Hsp82 binding partners. 
RAC also showed interactions with other gentamicin-binding proteins via a 
network found using the Osprey software program (Figure 14C), especially the 
interactions between Ssa1, Ssa2, Ssb1 and Sse1, which all have homology to gentamicin-
binding protein Hsp73 in mammals.  This network may also explain the presence of Tsa1 
on the gentamicin-binding protein list through an interaction with Sse1.  A systematic 
study of the identification of protein complexes in S. cerevisiae also found that Clc1 can 
be in a protein complex with Sse1 (Gavin et al., 2002). 
Finally, Pdi1, which is a homologue of the gentamicin-binding protein PDI, did 
not show an interaction with any of the remaining gentamicin-binding proteins. 
By both functional protein complex analysis and protein-protein interaction 
networks, and as confirmation of many previous studies, 62 out of 67 proteins on our 
gentamicin-binding protein list were verified or grouped into protein complexes.  The 
remaining ungrouped proteins are Mrp8, Rrs1, Crp1, Eno2 and Tif1.  The evidence from 
this study is not enough to support whether they directly or indirectly bind to gentamicin. 
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Mrp8 is a protein with unknown function.  Based on sequence analysis, Mrp8 is 
thought to be a mitochondrial ribosomal protein (Abraham et al., 1992). 
Rrs1 binds specifically to the ribosome protein L11 (RPL11) (Miyoshi et al., 
2004).  Rpl11 was not on our gentamicin-binding protein list but it is in the cytoplasmic 
ribosomal large subunit complex with eighteen other proteins on our list.  
Crp1 is a relatively unstudied protein.  The only report about Crp1 stated Crp1 is a 
cruciform DNA (X-DNA) binding protein (Rass & Kemper, 2002).   
Eno2 is a phosphopyruvate hydratase that catalyzes the conversion of 2-
phosphoglycerate to phosphoenolpyruvate in glycolysis and the reverse reaction during 
gluconeogenesis (Gomes et al., 2008). 
Tif1 (identical to Tif2) is a member of the translation initiation factor eIF4A (Neff 
& Sachs, 1999).  Other members of the eIF4A complex, Cdc33 or Tif4631, were not 
identified. 
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CHAPTER 4: STUDIES OF FOUR GENTAMICIN CONGENERS 
1   Effects of Gentamicin Congeners on Single Gene Deletion Strains 
At the present time, clinically available gentamicin is a mixture of four major 
gentamicin congeners, C1, C1a, C2 and C2a (Figure 1).  Studies have shown that different 
gentamicin congeners exhibit different cellular toxicities and nephrotoxicities in vivo 
(Sandoval et al., 2006), even though the congeners have very similar antimicrobial 
activities (Weinstein et al., 1967).  However, separation of the gentamicin congeners is 
technically difficult and expensive.  In this study, we started to examine the cellular 
toxicities of the congeners and tried to find the gentamicin congener least toxic to the 
mutants of our model system S. cerevisiae.  The result of this study will help us to meet 
the long-term goal of developing practical therapeutic approaches for better using 
gentamicin in the clinic. 
To begin the evaluation of how the gentamicin congeners affect S. cerevisiae , we 
selected four single gene deletion strains from S. cerevisiae that were previously found to 
be hypersensitive to gentamicin, zuo1∆, sac1∆, vps52∆, and vps16∆ (Wagner et al., 
2006).  Plate spot dilution assays of each strain were performed on YPD, YPD containing 
500 µg/ml gentamicin total mixture, or YPD containing 500 µg/ml gentamicin congener 
C1, C1a, C2 or C2a (Figure 15). 
While the wild-type strain was unaffected by the gentamicin total mixture or any 
of the gentamicin congeners, mutant cells were all sensitive to the gentamicin total 
mixture and all gentamicin congeners.  But clearly, the mutants were relatively more 
tolerant of gentamicin congener C1 than the other gentamicin congeners and the 
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gentamicin total mixture (Figure 15).  Interestingly, the gentamicin total mixture was 
more toxic than any single gentamicin congener. 
At present, we do not have further data to explain why gentamicin C1 is the least 
toxic gentamicin congener found in this study. 
2   Effects of Gentamicin Congeners on Arf-GEF and Arf-GAP Mutant Strains 
We also asked whether the different gentamicin congeners exhibit different levels 
of toxicity to yeast with impaired ARF1 pathway.  From our earlier studies, strain gea1-6 
gea1∆ gea2∆ and strain gcs1-28 gcs1∆ glo3∆ are hypersensitive to gentamicin (Results, 
Chapter 1).  Here, we tested both of the strains on YPGal, YPGal containing 500 µg/ml 
gentamicin total mixture, or YPGal containing 500 µg/ml gentamicin C1, C1a, C2 or C2a 
(Figure 16).  The results are consistent with the effects of the gentamicin congeners on 
single gene deletion strains, which is that mutant cells are less sensitive to gentamicin C1 
than the other gentamicin congeners or the gentamicin total mixture (Figure 16). 
3   Effects of Gentamicin Congeners on S. cerevisiae Strains with only hArf4 or 
bArf1 as Functional Arf 
Finally, we asked whether the different gentamicin congeners cause different 
toxicities to a yeast arf1∆ arf2∆ double deletion strain which is viable because of the 
expression of bARF1 or hARF4 under the GAL1 promoter (Results, Chapter 1).  Plate 
spot dilution assays were performed on both strains on YPGal, YPGal containing 500 
µg/ml gentamicin total mixture, or YPGal containing 500 µg/ml gentamicin C1, C1a, C2 or 
C2a (Figure 16).  These results are also consistent with the effects of the gentamicin 
congeners on single gene deletion strains and on the Arf-GEF or Arf-GAP mutant strains, 
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which is that mutant cells are less ssensitive to gentamicin C1 than the other gentamicin 
congeners or the gentamicin total mixture (Figure 16). 
So far, our conclusions regarding the toxicity of the four different gentamicin 
congeners is that gentamicin C1 is the least toxic congener among C1, C1a, C2 or C2a, and 
the vps52∆ strain exhibited greater sensitivity to the gentamicin total mixture than any 
single congener (Figure 15). 
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CONCLUSIONS 
The complete picture of how gentamicin induces nephrotoxicity involves multiple 
intracellular mechanisms.  Gentamicin is taken up through the endocytic pathway and 
then trafficked in a retrograde manner through the Golgi to the ER, from where it is 
finally released to the cytosol (Kahn et al., 1991; Moss & Vaughan, 1995).  It has been 
shown that gentamicin sequestered in the vacuoles or trafficked in a retrograde manner 
through the secretory pathway is nontoxic; however, the cytosol released gentamicin is 
toxic (Sandoval & Molitoris, 2004). 
In our model system S. cerevisiae, inspection of the physical and genetic 
interactions of the gentamicin sensitive mutants revealed a network centered on the ARF1 
pathway (Figure 17).  Arf1 is a small GTPase and plays a key role in the regulation of 
retrograde and anterograde trafficking through the secretory pathway.  Our studies show 
that arf1
ts
 arf1∆ arf2∆ cells, gea1ts gea1∆ gea2∆ cells, and gcs1ts gcs1∆ glo3∆ cells are 
all hypersensitive to gentamicin, which indicates that impaired Arf1 function causes yeast 
to become hypersensitive to gentamicin.  As evidence, cellular CPY trafficking and 
processing are blocked by the presence of gentamicin in arf2∆, arf1-11 arf1∆ arf2∆, 
arf1-18 arf1∆ arf2∆, gea1∆, gea1-6 gea1∆ gea2∆, glo3∆, and age2∆ mutant strains.  
Interestingly, gentamicin can directly affect the level of GTP-bound Arf1 in a growth 
phase-dependent manner, even though the total Arf1 level is not affected.  As predicted, 
we also find that gentamicin-bound resin can enrich both yeast Arf1-TAP protein and rat 
Arf1 protein in vitro.  Furthermore, the binding of Arf1 to a gentamicin-bound resin is 
enhanced in a GTP/GDP-dependent manner.  The gentamicin hypersensitivity is also 
observed in S. cerevisiae double deletion strains that lacked both ARF1 and ARF2 but are 
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kept viable by the presence of hARF4 or bARF1, which supports the idea that some 
mammalian Arfs are more vulnerable to gentamicin and at least partially explains the 
increased sensitivity of mammalian cells to gentamicin. 
It is also our interest to clarify the effect of gentamicin on programmed ribosomal 
frameshifting efficiency since it has not been reported in the literature.  Our studies show 
that gentamicin increases -1 programmed ribosomal frameshifting efficiency by 3 fold 
but has virtually no effect on +1 programmed ribosomal frameshifting. 
With the help of mass spectrometry, we also generated a gentamicin-binding 
protein list.  Some of these proteins may contribute to gentamicin-induced intracellular 
toxicity. 
Finally, a comparison of a gentamicin mixture and four of the gentamicin 
congeners revealed that gentamicin C1 is less toxic than other gentamicin congeners or 
the gentamicin total mixture for single gene deletion strains, Arf-GEF and Arf-GAP 
mutant strains and strains with only hArf4 or bArf1 as functional Arf. 
There are still questions that remain unclear after this study.  Firstly, since 
Brefeldin A can stabilize the abortive Arf1-GDP-Sec7 domain complex and prevent Arf1 
from being activated (Chardin & McCormick, 1999), we hypothesize that gentamicin has 
a similar effect on the Arf1-Gea1/Gea2 complex.  This hypothesis may be also able to 
explain our observation that even though the total Arf1 level is not affected by 
gentamicin, GTP-bound Arf1 is significantly decreased at early-log and mid-log phase by 
the presence of gentamicin. 
It has been known for decades that intensive reabsorption of proteins filtered by 
the renal glomeruli takes place in the renal proximal tubules (reviewed in Chambers, 
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2001).  Also, the proximal tubule cell is one of the most endocytic mammalian cells.  We 
also hypothesize that in general, in comparison to S. cerevisiae, human proximal tubule 
cells are more sensitive to gentamicin, and the proximal tubule cells with impaired Arf1 
function are more vulnerable to gentamicin. 
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Table 1.  Yeast strains used in this study. 
 
Strain Genotype Reference 
121.13C 
MATα ade2-101 his3-Δ200 leu2-3,112 lys2-801 ura3-52 
arf1::HIS3 arf2::LEU2 (pJCB1-21*)Gal
+
 
(Kahn et al., 1991) 
APY022 
MATα ura3-52 leu2-3,112 his3-Δ200 lys2-801 ade2-101 
gea1-6 gea2::HIS3 
(Peyroche et al., 2001) 
BL2 MATα segregant of FY24XFY86 M. Goebl 
BY1437 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 age2::KanMX4 Open Biosystems 
BY2783 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 vps16::KanMX4 Open Biosystems 
BY3835 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 arf2::KanMX4 Open Biosystems 
BY3890 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 arf1::KanMX4 Open Biosystems 
BY4318 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 vps52::KanMX4 Open Biosystems 
BY4462 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 vps45::KanMX4 Open Biosystems 
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Open Biosystems 
BY5062 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 sac1::KanMX4 Open Biosystems 
BY5512 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 syt1::KanMX4 Open Biosystems 
BY5937 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 zuo1::KanMX4 Open Biosystems 
BY6121 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 glo3::KanMX4 Open Biosystems 
BY6829 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 gea1::KanMX4 Open Biosystems 
BY23528 
MATa/MATα his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 
ura3Δ0/ura3Δ0 met15Δ0/MET15 lys2Δ0/LYS2 
sec7Δ::kanMX4/SEC7 
Open Biosystems 
BY25401 
MATa/MATα his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 
ura3Δ0/ura3Δ0 met15Δ0/MET15 lys2Δ0/LYS2 
sec12Δ::kanMX4/SEC7 
Open Biosystems 
BY7499684 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 ARF1::TAP-
HIS3MX6 
Open Biosystems 
CJY49-3-4 MATα ura3-52 leu2-3,112 his3-Δ200 lys2-801 ade2-101 (Peyroche et al., 2001) 
CJY62-10-2 
MATα ura3-52 leu2-3,112 his3-Δ200 lys2-801 ade2-101 
gea1-4 gea2::HIS3 
(Peyroche et al., 2001) 
LLY231 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 pYDL-control This study 
LLY232 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 pYDL-LA This study 
LLY233 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 pYDL-TY1 This study 
NY966 MATα sec7-1 ura3 leu2 his3 P. Novick 
NYY0-1 
MATa ade2 ::ARF1::ADE2 arf1::HIS3 arf2::HIS3 ura3 
lys2 trp1 his3 leu2 
(Yahara et al., 2001) 
NYY11-2 
MATa ade2 ::arf1-11::ADE2 arf1::HIS3 arf2::HIS3 ura3 
lys2 trp1 his3 leu2 
(Yahara et al., 2001) 
NYY16-1 
MATa ade2 ::arf1-16::ADE2 arf1::HIS3 arf2::HIS3 ura3 
lys2 trp1 his3 leu2 
(Yahara et al., 2001) 
NYY18-1 
MATa ade2 ::arf1-18::ADE2 arf1::HIS3 arf2::HIS3 ura3 
lys2 trp1 his3 leu2 
(Yahara et al., 2001) 
PPY164-5A 
MATα ura3-1 leu2-3,112 his3--11 ade2-1 trp1-1 can1-100 
gcs1::URA3 pPP805-3 
(Poon et al., 1999) 
PPY164-5B 
MATα ura3-1 leu2-3,112 his3--11 ade2-1 trp1-1 can1-100 
age2::HIS3 pPP805-3 
(Poon et al., 1999) 
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PPY164-5C 
MATα ura3-1 leu2-3,112 his3--11 ade2-1 trp1-1 can1-100 
pPP805-3 
(Poon et al., 1999) 
PPY164-5D 
MATα ura3-1 leu2-3,112 his3--11 ade2-1 trp1-1 can1-100 
gcs1::URA3 age2::HIS3 pPP805-3 
(Poon et al., 1999) 
PPY147-28-2A 
MATα ura3-1 leu2-3,112 his3--11 ade2-1 trp1-1 
gcs1::URA3 glo3::HIS3 pPP805-28 
(Poon et al., 1999) 
PPY147-28-2C 
MATα ura3-1 leu2-3,112 his3--11 ade2-1 trp1-1 
gcs1::URA3 pPP805-28 
(Poon et al., 1999) 
PPY147-28-2D 
MATα ura3-1 leu2-3,112 his3--11 ade2-1 trp1-1 pPP805-
28 
(Poon et al., 1999) 
PPY147-28-8A 
MATα ura3-1 leu2-3,112 his3--11 ade2-1 trp1-1 
glo3::HIS3 pPP805-28 
(Poon et al., 1999) 
RT166 
MATα his3-Δ200 leu2-3,112 lys2-801 ura3-52 arf1::HIS3 
arf2::LEU2 (pJCH2-8**)Gal
+
 
(Kahn et al., 1991) 
 
* bARF1 coding region behind the GAL1 promoter. 
** hARF4 coding region behind the GAL1 promoter. 
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Table 2.  Plasmids used in this study. 
Plasmid 
Name 
Vector 
Yeast 
Marker 
Bacterial 
Marker 
Inserted Gene Source 
pAB382 pGEX5X none amp
R
 yGGA2
1-326
  
(Boman et al., 
2002) 
pLH-
hARF1 
pET15B none 
amp
R
 
tet
R
 
hARF1 This study 
pLH-
hARF4 
pET15B none 
amp
R
 
tet
R
 
hARF4 This study 
pLH-
yARF1 
pET15B none 
amp
R
 
tet
R
 
yARF1 This study 
pLH-
yENO2 
pET15B none 
amp
R
 
tet
R
 
yENO2 This study 
pLH-
yHSP82 
pET15B none 
amp
R
 
tet
R
 
yHSP82 This study 
pLH-
yHYP2 
pET15B none 
amp
R
 
tet
R
 
yHYP2 This study 
pLH-
ySSZ1 
pET15B none 
amp
R
 
tet
R
 
ySSZ1 This study 
pLH-
yTEF1 
pET15B none 
amp
R
 
tet
R
 
yTEF1 This study 
pLH-
yTIF1 
pET15B none 
amp
R
 
tet
R
 
yTIF1 This study 
pLH-
yZUO1 
pET15B none 
amp
R
 
tet
R
 
yZUO1 This study 
pYDL-
control 
p416 ADH URA3 amp
R
 
Renilla and Firefly luciferases 
(in the same reading frame) 
(Harger et al., 
2003) 
pYDL-
LA 
p416 ADH URA3 amp
R
 
Renilla and Firefly luciferases 
(in -1 reading frame) 
(Harger et al., 
2003) 
pYDL-
TY1 
p416 ADH URA3 amp
R
 
Renilla and Firefly luciferases 
(in +1 reading frame) 
(Harger et al., 
2003) 
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Control 
Sample 
Firefly 
RLU 
Renilla 
RLU 
F/R ratio 
1 717796 2307771 0.311034 
2 414405 1322295 0.313398 
3 586402 1831500 0.320176 
4 905938 2769500 0.327112 
5 694758 2081138 0.333836 
6 732090 2178084 0.336117 
7 421932 1240683 0.34008 
8 812577 2342299 0.346914 
9 595495 1690852 0.352186 
10 669172 1849428 0.361826 
11 668397 1842390 0.362788 
12 932510 2550584 0.365606 
13 909530 2444292 0.372104 
14 745376 1967815 0.378784 
    
 Ty1 
Sample 
Firefly 
RLU 
Renilla 
RLU 
F/R ratio 
1 96170 2846411 0.033786 
2 143285 4070607 0.035200 
3 58084 1635092 0.035523 
4 64985 1758197 0.036961 
5 123929 3262937 0.037981 
6 138644 3632607 0.038167 
7 84243 2198075 0.038326 
8 84243 2198075 0.038326 
9 116317 3023119 0.038476 
10 116249 2996642 0.038793 
11 119066 3058200 0.038933 
12 121291 3114520 0.038944 
13 111189 2769590 0.040146 
14 133793 3177878 0.042101 
L-A 
Sample 
Firefly 
RLU 
Renilla 
RLU 
F/R ratio 
1 8022 1266186 0.006336 
2 12388 1925884 0.006432 
3 10503 1579967 0.006648 
4 15329 2275735 0.006736 
5 12894 1867712 0.006904 
6 22026 3110498 0.007081 
7 13833 1926832 0.007179 
8 29570 3990270 0.007411 
9 11956 1610156 0.007425 
10 28261 3771724 0.007493 
11 14201 1870128 0.007594 
12 11215 1452647 0.00772 
13 13005 1681021 0.007736 
14 11220 1408544 0.007966 
15 13555 1689092 0.008025 
16 10812 1318009 0.008203 
17 13683 1667882 0.008204 
18 14232 1727467 0.008239 
19 15403 1853376 0.008311 
20 24893 2977446 0.008361 
21 11713 1389255 0.008431 
22 10790 1270140 0.008495 
23 16416 1899885 0.008641 
24 17895 2068124 0.008653 
25 22166 2427183 0.009132 
26 25455 2764349 0.009208 
27 12653 1355571 0.009334 
28 11962 1269407 0.009423 
29 15795 1636081 0.009654 
30 15555 1578738 0.009853 
31 15222 1516713 0.010036 
Table 3.  Measurements of Renilla and Firefly luciferases intensity in YPD media.  
S. cerevisiae strains LLY231 (pYDL-control), LLY232 (pYDL-LA) and LLY233 (pYDL-
TY1) were used in this study (Table 1).  For each sample, a single colony from one of the 
strains was picked up and cultured in 5 ml of YPD media overnight at 30°C.  The overnight 
culture was diluted by YPD media to 2×10
6
 cells/ml and incubated for another 6 hours at 
30°C to reach the mid-log phase (1×10
7
 cells/ml).  Cells were harvested and lysed.  The cell 
lysate was then applied to the Dual-Luciferase Reporter
®
 Assay System.  The data are raw 
readings from the Monolight
®
 2010 Luminometer (Analytical Luminescence Laboratory). 
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Control 
Sample 
Firefly 
RLU 
Renilla 
RLU 
F/R ratio 
 Ty1 
Sample 
Firefly 
RLU 
Renilla 
RLU 
F/R ratio 
1 630747 2449088 0.257544  1 27411 1294608 0.021173 
2 804651 3082345 0.261052  2 30062 1358901 0.022122 
3 487674 1815876 0.268561  3 32410 1455926 0.022261 
4 927003 3422932 0.270821  4 29301 1262561 0.023208 
5 795995 2934761 0.27123  5 35355 1511759 0.023387 
6 713326 2626553 0.271583  6 56122 2393392 0.023449 
7 605174 2205764 0.27436  7 42216 1778025 0.023743 
8 2363307 8565024 0.275925  8 40027 1638626 0.024427 
9 929589 3362538 0.276455  9 56195 2290520 0.024534 
10 590974 2090421 0.282706  10 72749 2866700 0.025377 
11 610200 2127193 0.286857  11 40800 1571500 0.025962 
12 835458 2907143 0.287381  12 38330 1471835 0.026042 
13 749989 2604095 0.288004  13 46589 1774488 0.026255 
14 726489 2499858 0.290612  14 35972 1360378 0.026443 
15 897658 3076759 0.291754  15 60968 2261809 0.026955 
16 1185118 3972372 0.29834  16 82847 3018492 0.027446 
17 576527 1925768 0.299375  17 44632 1610610 0.027711 
18 618283 2045126 0.30232  18 54652 1945162 0.028096 
19 694961 2296689 0.302593  19 40215 1418169 0.028357 
20 878120 2884758 0.3044  20 37855 1293899 0.029257 
21 452935 1415320 0.320023  21 59430 2030684 0.029266 
22 2241837 6905755 0.324633  22 43395 1458535 0.029752 
23 971055 2971475 0.326792  23 48025 1607887 0.029868 
     24 41310 1376125 0.030019 
     25 62706 2079921 0.030148 
     26 60128 1967387 0.030562 
Table 4.  Measurements of Renilla and Firefly luciferases intensity in YPD + 500 
µg/ml gentamicin media.  S. cerevisiae strains LLY231 (pYDL-control), LLY232 
(pYDL-LA) and LLY233 (pYDL-TY1) were used in this study (Table 1).  For each 
sample, a single colony from one of the strains was picked up and cultured in 5 ml of 
YPD (or YPD + 500 µg/ml gentamicin) media overnight at 30°C.  The overnight culture 
was diluted by YPD (or YPD + 500 µg/ml gentamicin) media to 2×10
6
 cells/ml and 
incubated for another 6 hours at 30°C to reach the mid-log phase (1×10
7
 cells/ml).  Cells 
were harvested and lysed.  The cell lysate was then applied to the Dual-Luciferase 
Reporter
®
 Assay System.  The data are raw readings from the Monolight
®
 2010 
Luminometer (Analytical Luminescence Laboratory). 
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L-A 
Sample 
Firefly 
RLU 
Renilla 
RLU 
F/R ratio 
1 3051 194881 0.015656 
2 6054 374748 0.016155 
3 2370 143394 0.016528 
4 62434 3592685 0.017378 
5 3277 186388 0.017582 
6 35256 1972481 0.017874 
7 5965 331178 0.018011 
8 6696 368393 0.018176 
9 4585 252021 0.018193 
10 58912 3227948 0.018251 
11 2969 156404 0.018983 
12 6256 326406 0.019166 
13 6151 314010 0.019589 
14 70212 3578533 0.019620 
15 5182 262910 0.019710 
16 70394 3564246 0.019750 
17 51632 2576480 0.020040 
18 5527 275058 0.020094 
19 7401 355240 0.020834 
20 75418 3522338 0.021411 
21 4832 222223 0.021744 
22 5672 259004 0.021899 
23 5863 264379 0.022176 
24 5876 262352 0.022397 
25 59505 2655739 0.022406 
26 7082 311658 0.022724 
27 5787 253072 0.022867 
28 75390 3274909 0.02302 
29 73423 3166655 0.023186 
30 90762 3880058 0.023392 
31 139469 5868686 0.023765 
32 6112 246061 0.024839 
33 6681 260280 0.025669 
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Without Gentamicin 
 
 
               With Gentamicin 
 
 
Control  +1 PRF   -1 PRF 
 
Control  +1 PRF  -1 PRF 
Firefly/Renilla  
luciferase 
intensity ratio 0.344 0.038 0.008 
 
0.289 0.026 0.020 
Frameshifting  
Efficiency 
 
11.0 ± 0.2% 2.3 ± 0.1% 
  
9.1 ± 0.2% 7.1 ± 0.2% 
        
 
Comparing gentamicin treated and untreated cells 
 
 
    Percentage change 
+1 PRF 
 
-17% 
 
-1 PRF 
 
+200% 
 
p-value 2.01×10
-22
 8.17×10
-26
 
Table 5.  Systematic analysis of the -1 PRF and +1 PRF efficiency in S. cerevisiae in 
the presence or absence of gentamicin (500 µg/ml).  The raw data of Renilla and Firefly 
luciferases intensity measurements are presented in Table 3 and Table 4.  Gentamicin 
caused a significant increase in -1 PRF (200%) but virtually no effect on +1 PRF. 
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Protein 
No. 
ORF Standard Name Subcellular localization 
Identified 
Before 
Protein 
Molecules/cell 
Protein 
Size 
1 YBL072C,YER102W RPS8 Cytoplasm  2E+04 22 kDa 
2 YBR031W,YDR012W RPL4 Cytoplasm  2E+05 39 kDa 
3 YCR088W ABP1 Punctate/Actin  6E+02 66 kDa 
4 YDL082W,YMR142C RPL13 Cytoplasm  1E+05 23 kDa 
5 YDL191W,YDL136W RPL35 Cytoplasm  2E+04 14 kDa 
6 YDL229W,YNL209W SSB1,SSB2 Cytoplasm √ 2E+05 67 kDa 
7 YDR382W RPP2B Cytoplasm  6E+05 11 kDa 
8 YEL054C,YDR418 RPL12 Cytoplasm  7E+04 18 kDa 
9 YER074W,YIL069C RPS24 Cytoplasm  6E+03 15 kDa 
10 YGR167W CLC1 Punctate/Late Golgi  3E+03 27 kDa 
11 YHL034C SBP1 Cytoplasm  1E+04 33 kDa 
12 YHR064C SSZ1 Cytoplasm √ 7E+04 51 kDa 
13 YHR146W CRP1 Cell periphery  3E+03 51 kDa 
14 YKL056C YKL056C Cytoplasm  3E+04 19 kDa 
15 YKL117W SBA1 Cytoplasm/Nucleus  3E+04 24 kDa 
16 YKL180W,YJL177W RPL17 Cytoplasm  2E+04 21 kDa 
17 YKR059W,YJL138C TIF1,TIF2 Cytoplasm  1E+05 45 kDa 
18 YLL024C SSA2 Cytoplasm/Nucleus √ 4E+05 69 kDa 
19 YML024W,YDR447C RPS17 Cytoplasm  3E+04 16 kDa 
20 YML028W TSA1 Cytoplasm/Punctate  4E+05 22 kDa 
21 YMR186W,YPL240C HSC82,HSP82 Cytoplasm √ 4E+05 81 kDa 
22 YNL079C TPM1 Unlocalized  3E+03 24 kDa 
23 YOL039W RPP2A Cytoplasm  4E+05 11 kDa 
24 YOL121C,YNL302C RPS19 Cytoplasm  3E+04 16 kDa 
25 YOR007C SGT2 Cytoplasm  9E+03 37 kDa 
26 YPL090C,YBR181C RPS6 Cytoplasm  7E+04 27 kDa 
27 YPL106C SSE1 Cytoplasm √ 7E+04 77 kDa 
28 YPR080W,YBR118W TEF1,TEF2 Cytoplasm  4E+02 50 kDa 
29 YAL005C SSA1 Cytoplasm √ 3E+05 70 kDa 
30 YBL047C EDE1 Punctate  1E+03 151 kDa 
31 YDL075W,YLR406C RPL31 Unlocalized  6E+04 13 kDa 
32 YDR099W,YER177W BMH2,BMH1 Cytoplasm/Nucleus  2E+05 31 kDa 
33 YDR168W CDC37 Cytoplasm  1E+04 58 kDa 
34 YER056C-A,YIL052C RPL34 Cytoplasm  2E+04 14 kDa 
35 YER165W PAB1 Cytoplasm  2E+05 64 kDa 
36 YGL031C,YGR148C RPL24A,RPL24B Cytoplasm  2E+05 18 kDa 
Table 6.  Summary of considered gentamicin-binding proteins from LC-MS/MS.  A total 
of 67 proteins were considered identified by LC-MS/MS as gentamicin-binding proteins.  All 
67 proteins are listed here by their systematic names.  Data of protein subcellular localization, 
abundance and size are from the Saccharomyces genome Database 
(http://www.yeastgenome.org/). 
90 
 
37 YGR285C ZUO1 Cytoplasm  9E+04 49 kDa 
38 YHL033C,YLL045C RPL8A,RPL8B Cytoplasm  2E+05 28 kDa 
39 YHR174W ENO2 Cytoplasm  3E+03 47 kDa 
40 YHR203C RPS4 Cytoplasm  1E+05 29 kDa 
41 YIL070C MAM33 Mitochondrion  5E+03 30 kDa 
42 YJL034W KAR2 Ambiguous √ 3E+05 74 kDa 
43 YKL054C DEF1 Cytoplasm  3E+03 84 kDa 
44 YKL142W MRP8 Cytoplasm  2E+03 25 kDa 
45 YLR048W RPS0B Cytoplasm  6E+04 28 kDa 
46 YLR061W RPL22A Cytoplasm  6E+04 14 kDa 
47 YLR192C HCR1 Cytoplasm  2E+04 30 kDa 
48 YLR249W YEF3 Cytoplasm  9E+05 116 kDa 
49 YMR194W,YPL249C-A RPL36 Cytoplasm  5E+03 11 kDa 
50 YNL071W LAT1 Mitochondrion  5E+03 52 kDa 
51 YNL178W RPS3 Unlocalized  1E+05 27 kDa 
52 YOR096W RPS7A Cytoplasm  4E+04 22 kDa 
53 YOR332W VMA4 Vacuolar membrane  2E+04 26 kDa 
54 YPL081W,YBR189W RPS9 Cytoplasm  1E+05 22 kDa 
55 YPL143W,YOR234C RPL33 Unlocalized  7E+04 12 kDa 
56 YAL003W EFB1 Unlocalized  Not visualized 23 kDa 
57 YBR109C CMD1 Bud neck/cell periph./bud  Not visualized 16 kDa 
58 YCL043C PDI1 Cytoplasm/vacuole √ Low signal 58 kDa 
59 YEL034W HYP2 Unlocalized  Not visualized 17 kDa 
60 YGL103W RPL28 Unlocalized  Not visualized 17 kDa 
61 YJL020C BBC1 Unlocalized  Not visualized 128 kDa 
62 YJR123W RPS5 Unlocalized  Not visualized 25 kDa 
63 YLR259C HSP60 Mitochondrion  Not visualized 61 kDa 
64 YNL069C RPL16B Unlocalized  Not visualized 22 kDa 
65 YOL127W RPL25 
Bud neck/ cytoplasm/cell 
periph. 
 
Not visualized 16 kDa 
66 YOR294W RRS1 Unlocalized  Not visualized 23 kDa 
67 YOR369C RPS12 Unlocalized  Not visualized 16 kDa 
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Cytoplasmic ribosomal large subunit Cytoplasmic ribosomal small subunit 
 
YEL054C,YDR418 
 
RPL12 
 
YLR048W 
 
RPS0B 
YDL082W,YMR142C RPL13 YOR369C RPS12 
YNL069C RPL16B YML024W,YDR447C RPS17 
YKL180W,YJL177W RPL17 YOL121C,YNL302C RPS19 
YLR061W RPL22A YER074W,YIL069C RPS24 
YGL031C,YGR148C RPL24A,RPL24B YNL178W RPS3 
YOL127W RPL25 YHR203C RPS4 
YGL103W RPL28 YJR123W RPS5 
YDL075W,YLR406C RPL31 YPL090C,YBR181C RPS6 
YPL143W,YOR234C RPL33 YOR096W RPS7A 
YER056C-A,YIL052C RPL34 YBL072C,YER102W RPS8 
YDL191W,YDL136W RPL35 YPL081W,YBR189W RPS9 
YMR194W,YPL249C-A RPL36   
YBR031W,YDR012W RPL4   
YHL033C,YLL045C RPL8A,RPL8B   
YOL039W RPP2A   
YDR382W RPP2B   
Table 7.  Gentamicin-binding proteins of the cytoplasmic ribosomal large 
subunit and the cytoplasmic ribosomal small subunit. 
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Figure 1.  Chemical structures of gentamicin sulfate salt C1, C1a, C2, C2a and C2b.  
The amine groups of gentamicin sugar rings exhibit variable pKa values that range from 
5.6 to 9.5.  The amine groups on ring I are the most basic (pKa ~ 9.6), whereas those on 
ring II (pKa ~ 5.6 to ~ 8.0) and ring III (pKa ~ 7.5) have pKa‟s closer to physiological 
pH.  Gentamicin thus carries a net positive charge under physiological conditions (pH 
7.4).  
Ring I 
Ring II 
Ring III 
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Figure 2.  Plasmids used in the in vivo dual-luciferase assay.  A. pYDL-control was 
used as control plasmid in this study.  B. pYDL-LA has a special sequence, X XXY 
YYZ (the 0-frame is indicated by spaces), which is called a „slippery site‟.  An mRNA 
pseudoknot secondary structure is located immediately 3‟ to the slippery site, and the 
pseudoknot could transiently pause the ribosome, and then cause -1 ribosomal 
frameshifting during translation.  C. During mRNA translation, the ribosome could slip 
+1 between CUU and UUA (both Leucine codons).  The slippage occurs during a 
translational pause induced by the slow recognition and low availability of the next in-
frame peptidyl-tRNAAGG (Arg). (Modified from Dinman et al., 2006). 
A. pYDL-control 
B. pYDL-LA 
C. pYDL-TY1 
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Figure 3.  Genetic/Physical network of genes necessary for gentamicin resistance.  
The single deletion of solid boxed genes is found to exhibit gentamicin sensitivity by 
Blackburn and Avery (2003). 
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Figure 4.  Sensitivity of yeast ARF1 arf2∆ and arf1ts arf1∆ arf2∆ strains to 
gentamicin. A. ARF1 arf2∆ (NYY0-1) and arf1ts arf1∆ arf2∆ strains (NYY11-2, 
NYY16-1, or NYY18-1, respectively) (Table 1) were cultured overnight in liquid YPD 
medium.  30 µl of each overnight culture were transferred to fresh YPD medium plates 
and grown at their permissive temperature (RT-room temperature) or non-permissive 
temperature (37ºC).  Images were captured on the second day (for 37ºC incubation) or 
the fourth day (for RT incubation).  B. Same strains were cultured overnight in liquid 
YPD medium.  A certain number of cells (as indicated) were transferred to fresh YPD 
medium plates containing different concentrations of gentamicin (none, 100 µg/ml, 250 
µg/ml and 500 µg/ml, respectively).  The plates were incubated at their permissive 
temperature (RT) and images were captured on the fourth day. 
ARF1 arf2∆ 
arf1-11 arf2∆ 
arf1-16 arf2∆ 
arf1-18 arf2∆    
ARF1  
arf1-11  
arf1-16  
arf1-18    
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D129E and E41V 
H80P 
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Figure 5.  Change in GTP-bound Arf1 levels during different cell growth phases.  
A. GTP-bound Arf1 levels is lower at early-log to mid-log growth phase in the 
presence of gentamicin (500 µg/ml).  B. In different growth phases, total Arf1 
expression level remains stable, regardless of the presence of gentamicin (500 µg/ml).  
C. Scanning densitometry analysis of Panel A. 
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Figure 6.  Gentamicin sensitivity of single gene deletion strains in different growth 
phases.  Cells from different growth phases were placed on YPD plates in the absence or 
presence of gentamicin.  sac1∆ strain is sensitive to 50 µg/ml of gentamicin; vps52∆ strain 
is sensitive to 50 µg/ml of gentamicin and is more sensitive at mid-log and late-log phases; 
vps16∆ strain is sensitive to 100 µg/ml of gentamicin and is more sensitive at mid-log and 
late-log phases; and zuo1∆ strain is sensitive to 50 µg/ml of gentamicin and is more 
sensitive at late-log phase. 
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Figure 7.  Gentamicin sensitivity of yeast Arf-GEF mutants. gea1-4 gea1∆ gea2∆ 
mutant strain has multiple substitutions including two in the highly conserved Sec7 
domain (Peyroche et al., 2001).  The gea1-6 gea1∆ gea2∆ mutant has two amino acid 
substitutions downstream of the Sec7 domain (Peyroche et al., 2001).  The sec7-1 
mutant has substitutions outside of the Sec7 domain (Deitz et al., 2000).  At its 
permissive temperature (32ºC), gea1-6 gea1∆ gea2∆ cells are sensitive to gentamicin. 
YPD + Gentamicin (500 µg/ml) YPD  
BY4741 (WT) 
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Figure 8.  Gentamicin sensitivity of yeast Arf-GAP mutants. Gcs1 and Age2 form 
an Arf-GAP pair which provides an overlapping function for vesicle transport from the 
trans-Golgi network to the vacuole and late endosomes (Poon et al., 2001).  Gcs1 and 
Glo3 form another Arf-GAP pair which provides an overlapping function for vesicle 
retrograde transport from the Golgi to the ER (Poon et al., 1999).  The gcs1-28 
gcs1∆glo3∆ strain showed strong growth inhibition at a gentamicin concentration of 
250 µg/ml. 
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Figure 9.  Gentamicin sensitivity of Arf-GEF and Arf-GAP mutants in different growth 
phases.  Cells from different growth phases were placed on YPD plates in the absence or 
presence of gentamicin at their permissive temperature (30ºC). 
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Figure 10.  Disruption of cellular CPY processing in Arfs, Arf-GAP, or Arf-GEF 
mutants by gentamicin.  Strains were grown at their permissive temperature to early-log 
phase (5×10
6
 cells/ml) before gentamicin (to a final concentration of 500 µg/ml) was 
added to the medium.  After 0, 4 or 8 hr of additional incubation, aliquots of cells were 
removed and prepared for Western Blot analysis using anti-CPY as primary antibody. 
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Figure 11.  Enrichment of the yArf1-TAP protein and rat Arf1 protein by gentamicin-
bound resin.  Incubated with yeast Arf1-TAP strain, after four consecutive washes, the 
elution (by 10 mM gentamicin in the lysis buffer) from A. gentamicin-bound resin, B. 
empty (negative control) resin, C. gentamicin-bound resin with in vitro added GDP (10mM) 
and D. gentamicin-bound resin with in vitro added GTPɤS (10mM).  A & B suggest that 
gentamicin-bound resin can enrich Arf1-TAP protein in vitro.  C & D suggest that Arf1-
TAP protein binding to gentamicin-bound resin is enhanced in a GTP/GDP-independent 
manner.  E. Rat cytosol was incubated with gentamicin-bound resin.  After four consecutive 
washes, the elution (by 10 mM gentamicin in the lysis buffer) was blotted by the rabbit anti-
ratArf1 antibody or rabbit pre-immune serum (as negative control). 
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Figure 12.  Gentamicin sensitivity of S. cerevisiae strains with only hArf4 or 
bArf1 as functional Arf.  Strain hArf4 yarf1∆ yarf2∆ (RT166 in Table 1) and strain 
bArf1 yarf1∆ yarf2∆ (121.13C in Table 1) were cultured at room temperature to 
early-log, mid-log or late-log phase before the plate spot dilution assays.  Media 
plates were incubated at room temperature and the images were taken on day 3. 
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Figure 13. Evaluation of the gentamicin-binding protein list. A. Gentamicin-
binding protein expression level. Gentamicin-binding proteins (listed by Protein No. 
from Table 6) are plotted against their protein expression level (molecules/cell).  
Protein No.1 to No.28 are detected and identified by LC-MS/MS more than three 
times.  Protein No.29 to No.55 are detected and identified by LC-MS/MS fewer or 
equal to three times.  Protein ID No.56 to No.67 are lack of protein expression data.  
B. Smaller proteins (Mr < 35,000) were successfully identified.  The limitation of LC-
MS/MS in identifying smaller proteins (Mr < 35,000) was not observed in our 
gentamicin-binding protein list.  Over half of the proteins identified from this study are 
smaller proteins (Mr < 35,000). 
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Figure 14. Functional gentamicin-binding protein complexes and protein networks.  
A. Efb1 and Tef1 (identical to Tef2) are members of the eukaryotic elongation factor-1 
(eEF-1) complex. The network generated by Osprey revealed eight proteins, Yef3, Hyp2, 
Pab1, Sbp1, Mam33, Cmd1, Tpm1 and Ede1, that can be eEF-1 binding partners.  Also, 
Abp1 and YKL056C encoding protein were found with Hyp2 and Ede1 in the same 
protein complex (Costanzo et al., 2010).  Bbc1 is in another protein complex with Hyp2 
(Gruhler et al., 2002).  B. Hsc82p and Hsp82p are homologs of GRP94, which has 
shown the binding ability to gentamicin in a previous study (Horibe et al., 2004). Nine 
more proteins (Bmh1, Def1, Sba1, Vma4, Hsp60, Hcr1, Lat1, Sgt2 and Cdc37) were 
grouped as Hsc82 and Hsp82 binding partners.  C. The ribosome-associated chaperone 
(RAC) complex.  Ssa1, Ssa2, Ssb1 and Sse1 are homologs to HSP73, which has shown 
the binding ability to gentamicin in a previous study (Miyazaki et al., 2004).  Zuo1 is 
also in our protein list.  Based on the Osprey software program, Tsa1 has a protein-
protein interaction with Sse1. 
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Figure 17.  Model of S. cerevisiae in response to gentamicin.  (  , CPY).  Arf1 
pathway (in red) is a target of gentamicin in eukaryotic cells.  Different Arf-GEF and 
Arf-GAP are responsible for different steps in the anterograde and retrograde traffic.  
Gentamicin affects the retrograde traffic from the Golgi to the ER significantly.  Protein 
sorting (CPY as a molecular marker) is also affected and blocked by gentamicin as a 
consequence of the ineffective retrieving of ER lumenal and ER membrane proteins. 
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